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ABSTRACT 
 
The human cytomegalovirus (HCMV) viral chemokine gene, UL146, 
shows a high degree of variability in clinical isolates.  The UL146-produced viral 
chemokine, vCXCL-1, has homology to CXC chemokines and is predicted to be 
an immune modulator that may contribute to the pathogenesis of HCMV 
infections.  In the analysis of clinical isolates from congenitally infected infants, 
we found 11 distinct vCXCL-1 clades.  Although the four cysteine residues that 
create two disulfide bonds providing the essential structure for CXC 
chemokines,are conserved, the N-loop region, which is important for receptor 
binding and activation, was hypervariable.  One clade also contained a modified 
glutamic acid-leucine-arginine (ELR) motif (asparagine-glycine-arginine / NGR), 
which regulates binding to CXCR1 and CXCR2 receptors.  Based on this 
sequence information, we hypothesize that these proteins differentially activate 
neutrophils, which may have a role in HCMV pathogenesis.  To address these 
functional differences, we produced representative vCXCL-1 proteins from each 
of the 11 clades using a baculovirus protein expression system.  Using 
competition binding assays, we have examined their binding affinities to either 
CXCR1 or CXCR2 expressed on HEK293 cells. All vCXCL-1s bound to CXCR2 
with different binding affinities. Interestingly, only three vCXCL-1s bound to 
CXCR1 while the others demonstrated did not.  We analyzed functional 
differences between the vCXCL-1s in calcium mobilization, adhesion molecule 
induction, and chemotaxis on human peripheral blood neutrophils (PBNs).  
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Although the binding affinities to CXCR2 and/or CXCR1 were variable, all 
vCXCL-1s were capable of inducing intracellular calcium mobilization in PBNs 
and upregulating adhesion molecules on the surface of PBNs to similar levels as 
human CXCL1.  However, the potency of the vCXCL-1s in the chemotaxis of 
neutrophils varied and was affinity independent.  We also examined secondary 
chemokine production upon vCXCL-1 treatment on neutrophil-like HL60 T2 cells 
using real-time PCR.  The results showed CCL22 induction was affinity 
dependent.  Taken together, these results provide insights into the potential role 
of vCXCL-1 in HCMV pathogenesis and how the variability in these chemokines 
can affect neutrophil function. 
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Chapter 1 
INTRODUCTION 
 
Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus 
infecting 50-90% of the population with higher infection rates found in people with 
lower socioeconomic status.  Generally, HCMV infection is generally 
asymptomatic or causing mononucleosis in immunocompetent individuals, but 
high levels of morbidity and mortality rates are observed in immunocompromised 
individuals following organ transplantation or untreated HIV infection.  For 
example, 80% of kidney recipients acquire a primary CMV infection following 
transplantation [1] and an 84% mortality rate was observed in bone marrow 
recipients [2, 3].  Also, HCMV disease occurred in 44% of AIDS patients before 
the introduction of antiretroviral therapy [4].  In addition, HCMV is the most 
common congenitally acquired infection in the United States.  Each year, about 
1% of all newborns in the United States are infected with HCMV congenitally [5], 
reaching almost 40,000 newborns per year [6].  0.1% of these infected infants 
display clinical manifestations at birth, such as microcephaly, 
hepatosplenomegaly, jaundice, petechiae, or chorioretinitis [7] and up to 80% of 
those develop long-term neurodevelopmental sequelae, such as lower 
intelligence/developmental quotient (IQ/DQ), hearing loss, or mental retardation 
[6, 8].  Newborns that are asymptomatic at birth also can develop permanent 
damage, which may not manifest until they are older [9].  Due to this high rate of 
disease development and lasting morbidity, the Institute of Medicine ranked the 
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development of a CMV vaccine as a top priority based on the overall cost of 
treatment and human suffering [10].  
HCMV is a large dsDNA virus that comprises 165-252 kb [11, 12].  HCMV 
encodes over 200 viral proteins [13, 14], yet they have evolved survival 
mechanisms to overcome host immune responses that eventually contribute to 
HCMV pathogenesis and disease development [15].  Yu et al showed 41 HCMV 
ORFs in the laboratory-adapted strain, AD169, that are essential for viral 
replication in vitro, such as DNA polymerase, capsid, matrix and envelope 
proteins [16].  He also found 88 “nonessential” genes for efficient HCMV 
replication in vitro.  Some of these nonessential HCMV genes are homologous to 
the host genes: class I MHC proteins [17-21], TCR gamma chain [22], IL-10 [23], 
TNF receptor [24], and chemokines [25].  Among those nonessential genes, the 
15 kb UL/b’ genomic region of the virulent Toledo strain contains at least 19 open 
reading frames (ORFs) which are not present in laboratory-adapted strains such 
as the AD169 strain [25, 26].  Two ORFs in this region show homology to host 
chemokines: UL146 and UL147 that encode vCXCL-1 (also called pUL146) and 
vCXCL-2 (also called pUL147) [25].  These chemokine homologs genes show 
hypervariability among different viral strains [27].  Moreover, the vCXCL-1 
chemokine from the Toledo strain, vCXCL-1Tol, induces neutrophil chemotaxis 
and calcium mobilization [28].  Therefore, evaluations of the function of vCXCL-
1s will provide a better understanding of HCMV pathogenesis that may ultimately 
facilitate development of an effective vaccine or novel antiviral agents against 
CMV.  
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Chapter 2 
LITERATURE REVIEW 
 
I. Chemokines and Chemokine Receptors 
Chemokines 
Chemokines are small chemotactic cytokines (approximately 8-12 kDa in 
size) that mediate their signaling through G-protein coupled receptors [29, 30].  
They are classified by the presence of conserved cysteines that define the 
protein structure.  Chemokines are divided into C, CC, CXC, and CX3C 
chemokines based on the number of conserved cysteine residues and the 
spacing of two cysteines at the N-terminus.  For example, CXC chemokine (α 
subfamily) members have two cysteines separated by an amino acid residue 
while the CC chemokine (β subfamily) has two juxtaposed cysteine residues.  
The C chemokine family (γ subfamily) has only one cysteine at the N-terminus 
and the CX3C chemokine (δ subfamily) contains two cysteines separated by 
three amino acids [31].  CXC chemokines can be further subdivided into ELR or 
non-ELR CXC chemokine dependent upon the presence of a glutamate-leucine-
arginine (ELR) motif directly preceding the CXC motif [32].   
The ELR motif is critical to induce activation and migration of neutrophils 
[32].  The ELR CXC chemokines bind to CXCR1 and/or CXCR2, and it has been 
shown that CXCR2 activation is mainly responsible for neutrophil activation [33]. 
Single amino acid substitutions in the ELR motif showed all three residues, 
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especially arginine, are sensitive to modification and are critically important for 
CXCL8 (IL-8) function [34, 35].  A further demonstration of the importance of this 
motif is that the addition of ELR to the N-terminal domain of a non-ELR CXC 
chemokine, CXCL4 (PF4), transforms it into a neutrophil chemoattractant [34] 
although another non-ELR CXC chemokine, CXCL10 (IP-10), requires additional 
Gly31 and Pro32 changes in order to become a fully functional chemokine on 
human neutrophils [36].  ELR CXC chemokines also have angiogenic properties.  
CXCL8 (IL-8), CXCL7 (NAP-2), CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3 
(GRO-γ) and CXCL5 (ENA-78) have been reported as proangiogenic agents 
through the recruitment of endothelial cells [37, 38].  Although, angiostatic 
activities of ELR CXC chemokines were also reported for CXCL1 (GRO-α), 
CXCL2 (GRO-β), and CXCL3 (GRO-γ) [39], the concentration was 1000-fold 
higher (1-10 uM) than what was used for its angiogenic activity (1-10 nM) [40, 
41].  This implies that at high concentrations ELR CXC chemokines are 
angiostatic while at low concentrations they are angiogenic. 
In contrast to ELR CXC chemokines, many non-ELR CXC chemokines 
have angiostatic properties and almost exclusively attract cells other than 
neutrophils [32, 40].  For instance, CXCL10 (IP-10) was reported to attract 
monocytes, T lymphocytes, and NK cells [42, 43].  CXCL9 (MIG) was shown to 
attract tumor-infiltrating T lymphocytes [44].  CXCL12 (SDF-1) stimulates the 
proliferation of B cell progenitors and was also termed PBSF (pre-B cell growth 
stimulating factor) [45].  Subsequent studies showed that synthetic CXCL12 also 
stimulates monocytes and peripheral blood lymphocytes through intracellular 
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calcium mobilization and chemotaxis [46, 47].  This illustrates the specificity that 
the ELR motif brings to chemokine function. 
The CC chemokines are the largest family of chemokines and attract a 
variety of cell types including monocytes, basophils, eosinophils, and dendritic 
cells [48].  CCL2 (MCP-1) was the first CC chemokine to be biologically 
characterized and shown to attract monocytes but not neutrophils [49].  The 
monocyte chemotactic proteins (MCPs) are not only effective on monocytes [50-
52], but also attract CD4+ and CD8+ T lymphocytes [53-55] and basophils [56-
59].  CCL5 (RANTES) [60] and CCL11 (eotaxin) [61] were also shown to be 
powerful attractants of eosinophils.  
The C and CX3C chemokines are regarded as two minor families because 
they contain few members and are highly specific for a few receptors.  The CX3C 
family has three amino acids separating the initial pair of cysteines and has only 
one member, CX3CL1 (fractalkine) [62].  CX3CL1 is produced as a long protein 
(373 amino acid) with an extended mucin-like stalk and a chemokine domain on 
top [62].  CX3CL1 is bound to the surface of cells, such as endothelial cells and 
promotes strong adhesion of leukocytes to endothelial cells.  This membrane-
bound CX3CL1 can also be cleaved and become a soluble chemokine (85 or 95 
kDa) that attracts T cells and monocytes [62-64].  
Lastly, the C chemokine family is represented by two chemokines, XCL1 
(lymphotactin α) and XCL2 (lymphotactin β).  They lack two of the four cysteine 
residues that are characteristic of chemokines [65].  Lymphotactin is expressed 
in progenitor T cells, activated CD8+ T cells, and natural killer (NK) cells [65, 66].  
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It has been shown to be a potent chemoattractant for both CD4+ and CD8+ T 
cells, natural killer (NK) cells, but not monocytes [65, 67-69]. Lymphotactin has 
also been reported to be chemotactic for B cells and neutrophils through XCR1 
receptor [70]. 
 
Chemokine Receptors 
Chemokines mediate their signals through 7 transmembrane G-protein 
coupled receptors (GPCR).  Since GPCRs are generally known to be 
promiscuous for their ligands, it is reasonable that there are fewer receptors than 
chemokines [71].  Complex and multiple downstream signaling events, however, 
are possible due to the large number of heterotrimeric G proteins, such as α, β, 
and γ subunits, and β-arrestin [72, 73].  To date, 17 Gα, 5 Gβ, and 12 Gγ proteins 
have been found [73, 74].  Chemokine binding to a GPCR induces 
conformational changes and triggers its function as a guanine-nucleotide 
exchange factor (GEF) that exchanges GDP for GTP on the Gα subunit.  This 
exchange causes the dissociation of the Gα subunit from the Gβγ dimer, both of 
which activate several down stream effectors [75, 76].  In addition to GTP 
mediated signaling, G protein receptor kinases (GRKs) and β-arrestins also 
control signaling [77].  GRKs phosphorylates serine and threonine residues in the 
C-terminus allowing β-arrestin binding.  β-arrestins then prevent association of 
the G protein with the GPCR (desensitization) [78].  Additionally, the GRK-
arrestin system promotes clathrin-mediated internalization of the inactivated 
GPCR to endosomal compartments for subsequent degradation or recycling to 
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the cell surface [79, 80].  Interestingly, β-arrestins have also been shown to act 
as adaptor proteins mediating signaling events downstream of the GPCR, 
independently of G proteins activating mitogen-activated protein kinases 
(MAPKs), SRC, nuclear factor-κB (NF-κB) and phosphoinositide 3-kinase (PI3K) 
[78, 81, 82].  Therefore, various ligand binding with multiple combinations of G 
proteins and complex signaling pathways from G proteins and β-arrestins can 
generate numerous cellular effects from a similar ligands (Fig. 1). 
Once the Gα subunit and the Gβγ dimer are dissociated, the Gα subunit 
remains in the activated GTP-bound state until hydrolysis of GTP to GDP leads 
to reassociation of the heterotrimer and termination of the signal by the regulator 
of G-protein signaling protein (RGS) [83].  The α subunits of G proteins are 
divided into four subfamilies: Gαs, Gαi/o, Gαq/11, and Gα12/13.  Each Gα protein 
activates several downstream effectors.  Typically Gαs protein stimulates 
adenylyl cyclase (AC) and increases levels of cyclic AMP (cAMP) that 
subsequently activates mitogen-activated protein kinase (MAPK) signaling 
modules and protein kinase A (PKA) [84].  However, Gαi/o inhibits AC and 
reduces cAMP levels that subsequently activates G-protein-coupled inwardly 
rectifying potassium (GIRK) channels [85].  Gαq/11 protein activates 
phospholipase Cβ (PLCβ), and Gα12/13 subunit activates Rho guanine-nucleotide 
exchange factors (GEFs) [86].  8 Gα proteins are ubiquitous or widely distributed, 
but 9 Gα proteins are expressed in selective cell types, such as neuronal cells, 
retinal cells, or haematopoietic cells, etc (supplementary information of [87]). In 
summary, GPCRs can induce differential signalings via activation of various G
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Figure 1. Basic scheme for GPCR activation and feedback of signaling. 
Agonist exposure stimulates activation of GPCR, which leads to the dissociation 
of G proteins into activated subunit and dimers and triggers the activation of 
various effectors, such as adenylate cyclase and phospholipase C.  The agonist-
occupied GPCR is phosphorylated by GRKs, leading to signal desensitization, 
binding of β-arrestin to the activated, phosphorylated GPCR and subsequent 
endocytosis of the receptor. β-arrestin also initiate downstream signaling events. 
(adopted from Ma and Pei, 2007). 
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proteins that would also depend on the presence of specific G proteins in the cell  
as well as the right GPCR conformation to stimulate different G proteins.  
Dissociated Gβγ subunits also regulate a number of signaling pathways.  
Gβγ mediates the phosphorylation of PLCβ as Gαq does [88, 89].  Activated 
PLCβ cleaves phosphotidylinositol 4,5-bisphosphate (PIP2) to inositol 
triphosphate (IP3) and diacylglycerol (DAG).  IP3 elicits calcium mobilization from 
the endoplasmic reticulum (ER) into the cytoplasm, while DAG activates protein 
kinase C (PKC) [90].  Transient intracellular calcium mobilization is frequently 
used as a marker of cellular activation [91], whereas PKC activation is required to 
upregulate β2 integrins, such as CD11b/CD18, in neutrophils and eosinophils 
[92, 93].  In addition, Gβγ also stimulates Akt through phosphatidylinositol 3-
kinase (PI3K) as Gαs does through PKA [74].  It has been demonstrated that Akt 
activation as well as ERK are responsible for chemotaxis of HL60 cells or 
CXCR2 transfected HEK293 cells [94, 95].  As there are various Gα proteins, 
there are 5 Gβ and 12 Gγ proteins that can compose numerous combinations 
[73, 87].  Gβ and Gγ proteins are widely distributed except 1 Gβ and 5 Gγ 
proteins are expressed in selective tissues, such as brain or taste buds 
(supplementary information of [87]).  Therefore, overlapping signaling cascades 
through Gβγ can also increase the complexity of the signaling pathway. 
 
CXC chemokine and chemokine receptor interaction 
GPCR activation requires interaction with specific domains on the 
chemokines.  The N-terminus of both CC and CXC chemokines preceding the 
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first cysteine is considered an important region for receptor binding and activation 
[30, 96-100].  For instance, N-terminal truncation mutants of the CXC chemokine 
CXCL12 (SDF-1) revealed the eight residues proceeding first cysteine are 
essential for receptor binding and the deletion of the first two residues generates 
a receptor antagonist [101].  For CC chemokines, the entire 10 residues 
preceding the first cysteine in CCL2 (MCP-1) are strictly required for full activity 
[97, 98].  Manipulation of the N-terminus of CCL7 (MCP-3) and CCL5 (RANTES) 
produced potent antagonists [99, 100].  This included a single methionine, which 
converts CCL5 (RANTES) from an agonist to an antagonist.  Furthermore, in 
ELR CXC chemokines, mutations and domain swaps of CXCL1 (Groα) and 
CXCL8 (IL-8) revealed that the Glu-Leu-Arg (ELR) motif is a critical motif for 
receptor recognition and activation [102, 103].  Following the second cysteine is 
a flexible N-loop of approximately ten residues, which is followed by a single turn 
helix.  The N-loop region has been shown to be responsible for receptor binding 
and specificity [30, 35, 96, 104].  For example, Skelton et al. showed that CXCL8 
(IL-8) and CXCR1 N-terminus fragment, CXCR1-p1, are found to interact along 
the ELR and N-loop motifs of CXCL8 (IL-8) [105].  Furthermore, N-loop swaps 
between CXCL8 (IL-8) and CXCL1 (Gro-α) and mutations in this region 
demonstrated that the CXCL8 (IL-8) N-loop residues are critical for receptor 
specificity [106], indicating the ELR motif is necessary for receptor recognition 
and the N-loop region controls receptor specificity.  Nevertheless, other regions 
within the chemokine also contribute to receptor interactions as synthetic 
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peptides comprising the N-terminus and the N-loop have reduced activities 
compared to their full-length counterparts [32].   
Chemokines bind to glycosaminoglycans (GAGs) due to their cationic 
nature [107, 108].  CXCL8 (IL-8) binds to GAG through its C-terminal α-helix and 
shows enhanced chemotactic activity on neutrophils when complexed to heparan 
sulfate [109].  The GAG interaction on the cell surface or within the extracellular 
matrix is thought to facilitate the retention of chemokines and subsequently 
present it to the receptor expressed on the leukocyte cell surface, promoting cell 
adhesion and activation [110].  This will also create a solid support for chemokine 
gradients allowing the directed movement of cells under conditions of blood flow 
at the endothelial surface.  Several studies have shown the importance of GAG 
binding on chemokine function.  Gilat et al, using extracellular matrix (ECM)-
coated culture dishes, showed that CCL4 (MIP-1β) and CCL5 (RANTES) 
leukocyte adhesion and chemotaxis is GAG-dependent [111].  In addition, 
Proudfoot et al have shown that mutations in GAG binding sites of CCL2 (MCP-
1), CCL4 (MIP-1β), and CCL5 (RANTES) results in recruitment defects when 
injected into the peritoneum of mice while they retain chemotactic activity in vitro; 
thus, highlighting the importance of the chemokine-GAG interaction in vivo [112].   
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II. Viral immune evasion and pathogenesis 
Viral immune evasion 
Viruses replicate in a host cell pirating cellular resources.  In order to 
survive against host immune responses that recognize and eliminate virus-
infected cells, viruses have evolved strategies to overcome or manipulate the 
host immune system.  For instance, large DNA viruses such as β- and γ-
herpesviruses and some poxviruses have evolutionally acquired and modified 
host chemokines or chemokine receptors [113-115].  These virally encoded 
proteins are able to manipulate host immune responses, potentially leading to 
better viral dissemination and establishment of latency [114, 116, 117].  For 
dissemination purpose, viruses may attract immune cells through viral 
chemokines for infection and viral chemokine receptors to facilitate cell migration 
to sites of latency [114].  For immune system manipulation purposes, viruses 
may attract specific cell types, such as Th2 leukocytes, so that cytotoxic T cell 
(CTL) responses can be diminished [118, 119].   
 
Viral pathogenesis 
Herpesviruses are large double-stranded (ds) DNA viruses with 84–252 
open reading frames (ORFs) [115, 120, 121].  Herpesviruses replicate in the 
nucleus of the cell and undergo lytic replication and can establish latency.  
Following a primary productive infection, the virus is not completely eliminated 
from the host, but instead establishes a lifelong latent infection expressing only 
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minimum viral proteins in the absence of detectable infectious virus [122, 123]. It 
can reactivate at a later stage to generate new infectious virus and spread to a 
new host.  Herpesviruses are classified into three subfamilies, the α-, β-, and γ-
herpesvirinae based on their genetic organization, homology, and tropism [124].  
At least eight virus types are known to infect humans.  The α-herpesviruses 
include herpes simplex virus 1 and 2 (HSV-1 and HSV-2; HHV-1 and HHV-2) and 
varicella zoster virus (VZV, HHV-3).  These viruses remain latent in neurons. The 
β-herpesvirus subfamily includes cytomegalovirus (CMV, HHV-5), human 
herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7) and infects many cell 
types compared to α-herpesviruses.  Human CMV DNA has been found in a wide 
variety of organs [125]. Cells containing latent HCMV DNA has been found in 
monocyte/macrophage lineages [126-129] and hematopoietic progenitor cells 
[130-135].  In Murine CMV, latent DNA has been detected in endothelial cells of 
diverse organs including heart, kidney, liver, lung, spleen, brain, salivary glands, 
and bone marrow, and macrophages in the lungs [136, 137].  The γ-
herpesviruses include Epstein–Barr virus (EBV, HHV-4) and Kaposi’s sarcoma-
associated herpesvirus (KSHV, HHV-8).  They infect lymphocytes and 
endothelial cells and can induce cellular transformation [138].  
Poxviruses are also large dsDNA viruses with a 130–360 kbp genome that 
encodes over 230 proteins (See www.poxvirus.org for more detail).  In contrast to 
herpesviruses, poxvirus replication and the formation of progeny viruses take 
place in the cytoplasm, which is independent of the host nuclear machinery [117, 
139].  Poxviruses generally infect a variety animal hosts and causes acute 
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infections with abrupt onset of fever and skin lesions without establishing latency.  
Some families of poxvirus, however, can cause life-threatening infections.  
Variola virus, the causative agent of smallpox, was one of the most virulent 
human pathogens, with a mortality rate as high as 40%.  Vaccinia virus has been 
used as a vaccine and led to the 1979 eradication of smallpox worldwide [140]. 
Molluscum contagiosum virus (MCV) is the only poxvirus member that infects 
humans exclusively.  MCV commonly spreads through skin-to-skin contact 
causing skin lesions that are dome-shaped and pearly in appearance.  Infection 
is usually benign and painless.  The Orf virus causes disease with papulo-
vesicular lesions on the hand or face through direct contact with infected sheep 
and goats.  Often times when poxviruses cross species, disease is generally 
much more mild compared to the original host.  There are many more members 
of the poxvirus family, but are beyond the scope of this review.   Importantly, this 
large DNA virus family that causes acute infection produces an array immune 
modulating proteins similar to herpesviruses. 
 
III. Viral chemokine homologs  
CXC chemokine homologs in CMV 
Human CMV (HCMV) have two ORFs, UL146 and UL147, encoding CXC 
chemokine homologs, vCXCL-1 and vCXCL-2, respectively [25] (Table 1).  
Recently a presentation at the International Herpesvirus Workshop (Salt Lake 
City, 2010) indicated that vCXCL-2 is not secreted and is able to downregulate 
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Table 1. Cytomegalovirus chemokine-like genes (adapted from Beisser et 
al. 2008). 
CMV 
species 
Gene 
(product 
name) 
GenBank 
accession References Comments 
UL128 NC_006273 [141, 142] Intact in AD169, disrupted in Merlin and 
Toledo 
UL146  
(vCXCL–1) NC_006273 [143] 
Intact in Towne, Toledo, Merlin, lost in 
AD169 
HCMV 
UL147  
(vCXCL–2) NC_006273 [143] 
Intact in Towne, Toledo, Merlin, lost in 
AD169 
UL128 AF480884 [141, 142] Disrupted 
UL146   
(vCXCL–1)  AF480884  [144]   
UL146A  AF480884  [11] UL146-like, not present in other CMVs  
UL147 AF480884  [11]   
UL156  AF480884 [11] Splice variant may encode CXC 
chemokine, not present in other CMVs  
CCMV 
UL157  AF480884  [11] UL146-like, not present in other CMVs  
rhUL128 DQ120516 [145] Intact in RhCMV 180.92, not present in RhCMV68.1  
rh158  AY186194  [145] Intact in 68.1, not present in 180.92  RhCMV 
rh156.2  DQ120516 [145]  
r129 (RCK–
3/ ECK–3)   AF232689  [146]   
RCMV 
r131 (RCK–
2) AF232689 [146]   
MCMV 
m131–129  
(MCK–1;  
MCK–2)  
U68299  [147]   
GPCMV GPCMV-MIP AF500307 [148, 149]   Unique, MIP–1-like  
HHV–6  U83A  NC_001664  [150, 151]   
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NK activation with cooperation of UL142 [152].  Chimpanzee CMV (CCMV) also 
encodes homologs of UL146 and UL147 as well as the UL146-related gene 
UL146a and UL157 that are not present in other CMVs [11].  Rhesus CMV 
(RhCMV) encodes one homolog of UL147, rh158 [153].   It will be interesting to 
determine whether these homologues in other species have the same NK 
inhibitory functions as UL147 from HCMV.   
Yu et al showed that only 41 genes out of 150 ORFs in the lab-adapted 
AD169 strain are essential for efficient viral replication in vitro, which indicates 
many viral genes may be utilized for viral survival in vivo [16].  The virulent 
Toledo strain contains at least 19 open reading frames (ORF) in the 15 kb, UL/b’ 
region, which are not present in AD169 and are not essential for virus replication 
in vitro [25, 26].  This has lead to speculation that these genes may have a role in 
HCMV pathogenesis.  UL146 and UL147 chemokine genes reside in this UL/b’ 
[25]. UL146 ORF from the Toledo strain has been shown to produce a functional 
CXC chemokine called vCXCL-1Tol [143].  vCXCL-1Tol induced chemotaxis and 
intracellular calcium mobilization in human neutrophils at comparable levels to 
host chemokines.  Initially, vCXCL-1Tol was reported to bind exclusively to the 
human CXCR2 (hCXCR2) chemokine receptor [143].  However, Lüttichau et al 
recently showed that vCXCL-1Tol can bind not only hCXCR2 but also hCXCR1 
[154], similar to that of the host chemokine, CXCL8 (IL-8).  A deletion mutant of 
UL146-UL147 showed that it impairs viral passage to neutrophils while its 
tropism for other cell types is retained [142].  This result provides a potential role 
for vCXCL-1 in HCMV dissemination.   
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Interestingly, sequencing of the entire CMV genome has shown that the 
UL146 gene is one of the most variable genes in the entire HCMV genome [26, 
27, 155-160].  For instance, Dolan et al demonstrated HCMV genetic variability 
using a nucleotide divergence assay [27].  He showed high levels of variability in 
the RL11 gene families at left ends of UL and in the UL139, UL144, and UL146 at 
right ends of UL.  The proteins encoded by the RL11 gene family have potential 
roles in tropism [161]; a UL9 mutant from Towne grows better in HFFs than wild 
type virus while a UL10 mutant grows better in epithelial cells than wild type 
virus, although Yu et al did not find enhanced growth of UL9 mutants from AD169 
in HFFs [16], which is possibly due to the use of different parental viruses.  The 
UL139 protein shares sequence homology with human CD24 [162], a cell-
surface sialoglycoprotein.  It is expressed on immature cells modulating B-cell 
activation and on many cancers, such as non-small cell lung cancer, breast 
cancer, and prostatic cancer and correlates with tumor metastasis [163].  Qi et al, 
however, did not find an association between UL139 genotypes and the clinical 
outcomes [162].  The UL144 protein has limited homology to the herpes simplex 
virus entry mediator (HVEM), a member of the tumor necrosis factor receptor 
(TNFR) superfamily [164].  Research on an association between UL144 
genotypes and clinical outcomes showed no strong association [165-169] while 
Arav-Boger et al reported otherwise [156, 170].  Research regarding 
polymorphisms of UL146 from clinical isolates showed 4% identity (5 residues) 
and 5% similarity (6 residues) to each other [160].  It was postulated that this 
variability might correlate with the severity of CMV disease however no clear 
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relationship in this regard has been identified [158, 159, 165] and the function of 
the UL146 polymorphisms  remains to be determined.   
CC chemokine homologs in CMV 
HCMV has one ORF with limited homology to CC chemokine, UL128 [141], and 
UL130 that encode a protein containing a putative C chemokine fold [171].  
CCMV and RhCMV 180.92 also have a UL128 ORF with homology to CC 
chemokines [141, 142, 145].  Murine CMV (MCMV) contains spliced genes, 
m131 and m129, which produce the CC chemokine homolog, MCK-2 [147, 172]. 
Rat CMV (RCMV) also has both r131 and r129, but r131 has limited homology to 
either m131 and m129 [173].  Guinea pig CMV (GPCMV), also known as 
CavHV2_GP1, contains an ORF with limited homology to the CC chemokine 
MIP-1 [148, 174]. 
The HCMV UL128 protein, however, is a non-functional chemokine due to 
a partial inversion or frame shift mutation in clinical HCMV strains such as Toledo 
and Merlin [141].  Although the UL130 protein contains a putative C chemokine 
fold [171], functional data of UL130 as chemokine is lacking.  Interestingly, the 
UL128 locus (UL128L) that comprises UL128, UL130 and UL131A was found to 
be essential for growth in endothelial cells, dendritic cells and epithelial cells, and 
transmission to leukocytes [142, 175, 176].  The UL128L proteins form a complex 
with glycoprotein H and L (gH/gL) on the virion surface [177].  The gH/gL/UL128L 
complex mediates entry of CMV into endothelial and epithelial cells whereas the 
gH/gL/gO complexes mediate virus entry into fibroblasts [176, 177].  So even 
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though these have homology to chemokines, they more than likely have a role in 
entry. 
MCMV m131 and m129 genes generate a spliced mRNA that encodes the 
CC chemokine homolog, MCK-2 [147].  A product of m131, MCK-1, was 
originally described as a functional chemokine that induces calcium mobilization 
in peritoneal exudate cells in vitro from MCMV-infected mice [178].  MCK-1 was 
soon re-characterized as a part of a CC chemokine including a long carboxy-
terminal domain, which includes the entire m129 ORF [147, 172].  In vivo studies 
with MCMV mutants that delete m131/129 or a mutated m131 gene show a 
defect in dissemination to the salivary gland [179, 180] demonstrating that MCK-
2 is important for viral dissemination in vivo.  The mutant MCMV with a defective 
MCK-2 protein developed less inflammation at the site of inoculation and reduced 
dissemination to the salivary glands [179, 180].  MCK-2 can recruit myeloid 
progenitor cells [181] and monocytes [178], which not only contribute to MCMV 
dissemination to the salivary gland but could also provide a reservoir for 
establishing latency [130, 137, 182, 183]. 
As noted, RCMV contains the r131 gene that shows homology to both 
MCMV m131 and m129 [173].  The RCMV r131 ORF encodes a functional CC 
chemokine, pr131, which is essential for viral reproduction in the salivary glands 
[146].  When RCMV deletion mutants lacking r131 were inoculated into 
immunocompromised rats, RCMV was not able to establish a high-titer infection 
in the salivary gland.  In a rat footpad infection, this mutant showed significantly 
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reduced swelling than did wild type RCMV, which mimics what was shown for 
MCK-2 in MCMV. 
GPCMV encodes a unique, MIP-1 CC chemokine homolog, GPCMV-MIP, 
which is not conserved in other animal CMVs [148].  This gene encodes an 11 
kDa protein, which then yields an 8.6 kDa mature polypeptide.  Phylogenetic 
analysis indicated GPCMV-MIP has homology to the macrophage inflammatory 
protein 1 (MIP-1α / CCL3) and hemofiltrate CC-chemokine 1 (HCC-1 / CCL14).  
MIP-1α and HCC-1 are known to enhance the proliferation of CD34+ myeloid 
progenitor cells, which could be used to harbor latent GPCMV or to disseminate 
the virus in vivo [184].  Functional assays showed that GPCMV-MIP mobilizes 
equivalent levels of intracellular calcium mobilization and chemotaxis in hCCR1 
transfectants [149] as CCL3 (MIP-1α) stimulation [185].  However, GPCMV-MIP 
was not active on hCCR2 or hCCR5, which are the targets of CCL3 (MIP-1α).  
The intracochlear inoculation of a recombinant GPCMV lacking the GPCMV-MIP 
homolog resulted in less hearing loss compared to wild type GPCMV infection 
[186] indicating GPCMV-MIP has roles in CMV pathogenesis.  
 
CC chemokine homologs in other herpesviruses 
The U83 protein of human herpesvirus 6 (HHV-6) has a unique CXXCC 
sequence, which may be interpreted as a CC or/and CX3C chemokine [187].  
However, the protein product of U83 gene was designated vCCL4 because it 
causes intracellular calcium mobilization and chemotaxis exclusively through the 
CCR2 receptor [188].  The HHV-6A (variant A) U83 gene encodes a 97 amino 
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acid protein whereas HHV-6B (variant B) encodes one of 113 amino acids [189].  
As noted, vCCL4 of HHV-6B, also known as U83B while that of HHV-6A is U83A, 
is a selective but weak CCR2 agonist, inducing calcium mobilization and 
chemotaxis of THP-1 cells and CCR2 transfected L1.2 cells [187, 188].  CCR2 is 
expressed on monocytes, activated T cells, B cells, and immature dendritic cells 
[190, 191].  HHV-6 predominantly infects and replicates in CD4 T cells [192] and 
establishes latency in monocytes [193].  Furthermore, it has been shown that 
HHV-6 replication in immature monocyte-derived dendritic cells (MDDCs) is a 
prerequisite for viral transmission to CD4+ T cells [194].  Therefore, it seems 
sensible that vCCL4 attracts and HHV-6 utilizes those cells for viral 
dissemination or the establishment of latency.  Although HHV-6A also has 
cellular trophism for CD4+ T cell, its vCCL4 homolog (U83A) showed a broad 
specificity for the chemokine receptors CCR1, CCR4, CCR5, CCR6, and CCR8 
[151].  Because HHV-6A has been detected in skin biopsies and implicated in 
cases of multiple sclerosis (MS), the broad specificity of vCCL4 (U83A) suggests 
that its multiple cellular tropisms could contribute to pathogenesis of HHV6A.  
Interestingly, vCCL4 (U83A) can also manipulate the functions of host 
chemokines by delaying CCR5 internalization and blocking chemokine 
stimulation so this chemokine could be multi functional [151, 195].  
Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8) is responsible 
for the development of Kaposi’s sarcoma (KS, a cancer that causes patches of 
abnormal tissue to grow under the skin), primary effusion lymphoma (PEL, a rare 
aggressive type of B cell lymphoma), and multicentric Castleman’s disease 
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(MCD, a rare benign follicular hyperplasia in germinal centers of B-cell follicles) 
[196, 197].  KSHV encodes three CC chemokine homologs, vCCL1, 2, and 3 
(vMIP1, 2, and 3) [198-200].  KSHV chemokines antagonize or stimulate host 
chemokine receptors, induce angiogenesis, and reduce apoptosis as part of its 
immune manipulation.  vCCL1 (vMIP-1) is an agonist of CCR8 [198, 201, 202], 
which is preferentially expressed on TH2 cells [203].  By attracting Th2 cells the 
virus could limit activation of the Th1/CTL response allowing for increased 
survival. Both vCCL1 and vCCL2 are also potent chemoattractants for 
endothelial cells [204, 205], which appear to be required for angiogenesis and 
potentially contribute to tumor development [206].  Furthermore, vCCL1 and 
vCCL2 have anti-apoptotic effects in vitro.  These viral chemokines enhanced the 
survival rate of endothelial cells and therefore promoted viral replication [207].  
vCCL2 (vMIP-2) is a broad spectrum chemokine antagonist covering all four 
classes of chemokines (XCR, CCR, CXCR, and CX3CR), which are particularly 
found on Th1 cells [202, 208-210].  The efficient antagonistic activity of vCCL2 in 
vivo has been demonstrated in mouse and rat inflammatory models [209, 211, 
212].  However, others have shown that vCCL2 can bind and activate cells 
through CCR8, CCR3, and CCR5 present on Th2 cells, eosinophils, or cell lines 
[204, 213-215].  In fact, KSHV lesions expressing vCCL2 have a predominance 
of Th2 polarized cells compared to Th1 type cells based on cytokine profiles 
within the lesion [214].  vCCL3 (vMIP-3) was originally found to act with low 
potencies in CCR4 and CCR5 chemotaxis assays [200].  However, Lüttichau et 
al. were unable to demonstrate any calcium mobilization in L1.2 cells stably 
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transfected with those receptors but showed that vCCL3 selectively activates the 
XCR1 receptor with higher potency than the endogenous ligand XCL1 
(lymphotactin) [216].  
 
CC chemokine homologs in poxviruses 
In addition to herpesviruses, poxviruses also produce viral chemokines. 
Molloscum contagiosum virus (MCV) is a poxvirus that causes benign tumors of 
the skin or occasionally on mucous membranes.  It causes infections with a 
higher incidence in children and is an opportunistic infection in 
immunocompromised individuals [217].  MCV encodes a CC chemokine 
homolog, MC148 [218]. Sequence analysis originally predicted MC148 to be an 
antagonist because the N-terminus of the protein, a region important for receptor 
activation, is shorter compared to cellular CC chemokines [219].  In vitro analysis 
demonstrated that MC148 inhibits the migration of monocytes, lymphocytes, and 
neutrophils in response to a range of chemokines and is not an agonist for any of 
the CC or CXC receptors tested [219, 220].  However, Lüttichau et al. compared 
the antagonism of MC148 with its analog, a broad-spectrum chemokine 
antagonist vCCL2 from HHV-8, and demonstrated that CCR8 is the sole receptor 
for MC148 [208, 221].  Interestingly, vCCL2 attracts CCR8 expressing cells for 
viral dissemination and survival [213] while MC148 acts as an antagonist.  In fact, 
molloscum contagiosum lesions lack inflammatory infiltrates and MC148 might 
contribute to this feature of these lesions [222]. 
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Summary and Statement of Research Aims  
The development of a HCMV vaccine or other effective therapeutic 
treatment is upmost importance due to the high morbidity and mortality in HCMV 
infected newborns and immunocompromised individuals.  However, no vaccine 
against CMV is currently available despite over three decades of effort.  This is 
mainly due to the limited understanding of HCMV pathogenesis including viral 
dissemination.  HCMV dissemination occurs via cell-associated viremia in cells of 
hematopoietic origin including monocytes and neutrophils.  Large dsDNA viruses 
such as herpesviruses possess modified host chemokines that could alter the 
response of leukocytes during viral infection [84-86].  For example, MCMV, 
RCMV, and GPCMV encode CC chemokines such as MCK2, pr131, and 
GPCMV-MIP, respectively.  MCK2 and pr131 induce inflammatory responses 
that enhance virus dissemination to the salivary gland in vivo, while GPCMV-MIP 
showed the induction of inflammatory responses in the inner ear that leads to 
hearing loss. The UL146 ORF from the Toledo strain encodes a functional CXC 
chemokine called vCXCL-1Tol [143].  Moreover, vCXCL-1s from different HCMV 
strains showed hypervariability, which could be a determinant of HCMV 
pathogenesis.  Therefore, the analysis of the relationship between the vCXCL-1s 
polymorphism and the clinical manifestations may provide a key to developing a 
novel HCMV vaccine.  In addition, evaluating the function of those vCXCL-1s will 
broaden our understanding of HCMV pathogenesis in relation to immune evasion 
strategies. 
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The hypothesis of this dissertation is that polymorphisms of the viral 
chemokine, vCXCL-1, elicit different functions or different levels of cellular 
activation, which could contribute to HCMV pathogenesis.  To test this 
hypothesis, the following research objectives were performed: 
 
1. Analysis of the relationship between polymorphisms within human 
cytomegalovirus chemokine, vCXCL-1, and clinical manifestations in 
congenitally infected children. 
 
2. Expression of recombinant vCXCL-1s from different clinical isolates and 
evaluation of their functions as a chemokine in vitro. 
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Chapter 3 
POLYMORPHISMS WITHIN HUMAN CYTOMEGALOVIRUS 
CHEMOKINE (UL146/UL147) AND CYTOKINE RECEPTOR GENES 
(UL144) ARE NOT PREDICTIVE OF SEQUELAE IN 
CONGENITALLY INFECTED CHILDREN 
 
This chapter is a publication by the same title published in the journal 
Virology in 2008 by Jinho Heo, Susie Petheram, Gail Demmler, Jody R. Murph, 
Stuart P. Adler, James Bale, and Tim E. Sparer. 
Heo, J., Petheram, S., Demmler, G., Murph, J. R., Adler, S. P., Bale, J., 
and Sparer T. E., Polymorphisms within human cytomegalovirus chemokine 
(UL146/UL147) and cytokine receptor genes (UL144) are not predictive of 
sequelae in congenitally infected children. Virology. 378(1):86-96. 
My use of we in this chapter refers to my coauthors and myself. My 
primary contributions to this paper include (1) the majority of the lab work and (2) 
most of the data analysis, and (3) most of the writing of this paper. 
 
Abstract 
Human cytomegalovirus (HCMV) viral chemokine, UL146, and TNF α- like 
receptor UL144 genes show a high degree of hypervariability in clinical isolates.  
These proteins are predicted to be immune modulators and may contribute to the 
pathogenesis of HCMV infections.  We analyzed the UL146 and UL144 genetic 
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variation of 51 HCMV isolates from congenitally infected children and 13 isolates 
from children in childcare.  There was no statistically significant correlation 
between UL146 and UL144 genotypes and HCMV disease and/or sequelae. 
However, there were some groups that had a relatively large proportion of 
asymptomatic outcomes. These included UL146 group 8 (7/8 asymptomatic) and 
UL146 group 10 (3/3 asymptomatic).  UL144 group B had 11/15 (73%) 
asymptomatic.  UL146 and UL144 genes remained stable in serial isolates from 
children in daycare for intervals up to three years.  These results indicate that 
most UL146 and UL144 genotypes do not predict clinical sequelae following 
congenital HCMV infections.    
 
Introduction 
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus, 
congenitally infecting about 1% of all newborns in the United States [5].  0.1% of 
these infected infants display clinical manifestations at birth such as 
microcephaly, hepatosplenomegaly, jaundice, petechiae, or chorioretinitis [7].  Of 
those with clinical symptoms at birth, most develop long-term 
neurodevelopmental sequelae.  100% of these children will have lower 
intelligence/developmental quotient (IQ/DQ), 65% will have some hearing loss, 
and 53% will be diagnosed with mental retardation [6, 8].  Even those newborns 
that are asymptomatic at birth can develop clinical outcomes of hearing loss and 
learning disabilities, which may not manifest themselves until they are older [9].  
Due to this lasting morbidity, the Institute of Medicine recently ranked the 
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development of a CMV vaccine as a top priority based on the overall cost and 
human suffering [10].  To develop an adequate and effective vaccine or drug, a 
thorough understanding of the viral proteins that cause clinical disease are 
necessary.  
The outcomes of congenital HCMV infections are determined by a variety 
of factors.  Timing of infection, cell types infected at the placental interface [223, 
224], and maternal antibody titers [225] are among the factors that may affect 
clinical outcomes.  Several investigators have speculated that HCMV genes are 
important in the pathogenesis of human infections.  HCMV possesses genes that 
are predicted to be involved in immune evasion that could function to increase 
viral survival or spread [141, 171, 226-232].  There are a large number of open 
reading frames (~62) in HCMV that are “non essential” for virus replication in vitro 
but may have a role in immune evasion in vivo.  The 15 kb, UL/b’ genomic region 
of the virulent Toledo strain contains at least 19 open reading frames (ORFs) 
which are not present in laboratory-adapted strains such as the AD169 strain [25, 
26].  The products of two of these ORFs: vCXCL-1 (also called pUL146 and 
vCXC-1) from the UL146 gene and vCXCL-2 (also called pUL147 and vCXC-2) 
from the UL147 gene have limited homology to CXC chemokines [25].  UL147 
has only limited variability in the coding region of the mature protein.  Variability 
is limited to the signal sequence portion of UL147.  The vCXCL-1 chemokine 
from the Toledo strain, vCXCL-1Tol, induces neutrophil chemotaxis and calcium 
mobilization [28].  Recently, numerous HCMV genomes from clinical isolates 
have been sequenced [26, 155, 157-159, 233, 234] and have shown that the 
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UL146 gene, along with the UL139 [162] and UL144 genes, are some of the 
most variable genes in the entire HCMV genome.  The evolutionary reasons for 
this variability are unknown. 
 One hint of the role that vCXCL-1 plays during in vivo infection comes 
from early vaccine trials [235].  During this study, two strains, Toledo and Towne, 
were inoculated into naïve adult volunteers and the degree of febrile illness 
measured.  The outcome of this study showed that the Toledo strain generated 
febrile illness at a tenfold lower dose than Towne, implying that Toledo is more 
virulent than Towne.  When these genomes were sequenced, the UL146 genes 
were shown to be significantly different.  This example is commonly used as 
proof of the role that vCXCL-1 plays in HCMV pathogenesis.   
Because of the variability in UL146, it has been suggested that vCXCL-1 
proteins correlate with differences in long-term outcomes following congenital 
infections or during reactivation in immune compromised patients.  Several 
groups have analyzed the association between disease outcomes and UL146 
variability [155, 157-159, 233].  These clinical specimens were isolated from 
immunocompromised adults or congenitally infected newborns within first three 
weeks of life.  In adult renal transplant patients there was no correlation with 
clinical outcomes and UL146 genotypes [159].  In the congenital studies, the 
analysis did not take into consideration long-term sequelae. The analysis of 
congenitally infected infants was based solely on symptoms at birth [155, 157-
159, 233].  This could lead to an underestimate of the number of asymptomatic 
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children as HCMV infections leading to learning disabilities or mental retardation 
may not become apparent until months or years after birth [9].  
Another member of UL/b’ region, UL144, is also variable and a potential 
virulence factor [164].  This protein has limited similarity to the herpes simplex 
virus entry mediator (HVEM), a member of the tumor necrosis factor receptor 
superfamily (TNFRSF) [164].  The UL144 protein, however, does not bind any 
known TNF-related ligands [24, 164, 166].  To date, only one ligand, the Ig 
superfamily member B and T lymphocyte attenuator (BTLA), has been shown to 
bind to the UL144 protein [236].  By binding to BTLA, UL144 could decrease 
lymphocyte responses to HCMV.  Recently, UL144 has been shown to activate 
TNFR-activated factor 6 (TRAF6) leading to NFKB activation, a pleiotropic 
transcription factor [24].  NFKB activation enhances expression of the chemokine 
CCL22, which attracts Th2 and regulatory T cells diminishing Th1 response.  
Therefore, the authors speculate that upregulation of CCL22 may help HCMV 
evade immune surveillance, resulting in increased viral spread.  Data regarding 
the association between UL144 genotypes and the outcomes of congenital 
infection is conflicting.  While Arav-Boger et al reported an association [156, 170], 
others have not [165-169].   
Our study addresses whether an association exists between specific 
UL146, UL147, and UL144 genotypes and symptoms at birth in congenitally 
infected children.  Many of these children that were asymptomatic at birth were 
followed for several years to ensure there were no long-term sequelae.  In 
addition, serial isolates from children who shed HCMV over long periods of time 
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were analyzed to examine whether UL146 hypervariability is driven via immune 
pressure. 
 
Materials and Methods 
Clinical subjects and specimens 
HCMV isolates from symptomatic and asymptomatic congenitally infected 
children were obtained for phylogenetic analysis from two geographically distant 
locations at four facilities: 40 HCMV isolates from Iowa (four hospitals in Iowa 
City and Cedar Rapids, IA) and 11 isolates from Texas.  Six isolates from the  
Texas clinic were from a previous study [165].  Together, there are 18 
symptomatic (K.P., Sk, A.B., P.L., Ca, 100546, 101027, 102124, 102226, 102410, 
300584, TX03, TX11, TX12, TX20, TX21, TX24, and TX30) and 33 
asymptomatic children (100427, 100457, 100691, 100738, 100751, 101142, 
101329, 101430, 101465, 102429, 200164, 200550, 201334, 201370, 300016, 
300482, 300521, 300667, 301217, 301699, 302281, 400191, 400328, 400340, 
400600, 400818, 400865, 401058, 401361, TX05, TX15, TX25, and TX32) 
(Table 2).   
For the evolution of UL146 over time, 13 serial viral isolates from six 
children attending six day care centers in Virginia were grown in vitro and 
sequenced (Table 3). 
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DNA Isolation 
DNA was isolated from the Iowa and Texas clinical isolates as previously 
described [165].  HCMV infected MRC-5 cells from the Virginia Commonwealth 
University (VCU) study were maintained until 70 to 80% cytopathic effect (CPE) 
was attained.  Cold Tris/EDTA buffer (0.5 ml) with 10% SDS (50 ul) and 
proteinase K (100 ug/ml) was added to the cell pellets and incubated for one 
hour at 65°C.  Viral DNA was extracted using phenol/chloroform and precipitated 
with ethanol.  The DNA pellets were washed with 70% and dried.  DNA 
concentration was determined spectrophotometerically (A260/A280). 
 
PCR Amplification 
The primers for the UL146 and UL147 ORFs were designed for conserved 
regions that flank each of the ORFs.  The primers 5’-
GTCATGGACGCAGTTTTG-3’ (forward) and 5’-GAACGATCTCGTCCGGTTC-3’ 
(reverse) were identical to those used in Arav-Boger et al [158].  The size of the 
PCR product is 1.2-kb.  For the UL144 ORF, the primers 5’-
CGTATTACAAACCGCGGAGAGGAT-3’ (forward) and 5’-
CTCAGACACGGTTCCGTAAAGTG-3’ (reverse), which are located upstream or 
downstream of UL144 ORF, generate a 740-bp product.  The PCR conditions for 
UL146 and UL147 ORFs were 95ºC for 2 min, followed by 40 cycles of 95ºC for 
30 sec, 55ºC for 30 sec, 72ºC for 2 min.  The reaction was extended at 72ºC for 
10 min.  The UL144 PCR conditions were similar except the extension time was 
reduced to 1min. 
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DNA Sequencing 
The amplicons were cloned into the pGEM-T Easy vector using the 
pGEM-T Easy kit (Promega) according to the manufacturer’s instructions.  At 
least three colonies were picked and sequenced in both directions using 
universal primers (SP6 and T7).  For the serial isolates from VCU, if differences 
were identified in the UL146 ORF, the entire PCR reaction was repeated to 
ensure that any differences were due to differences in viral DNA and not due to a 
PCR amplification error.  All confirmed sequences were submitted to Genebank 
(Accession numbers: UL146: EU514891-EU514955; UL147: EU514794-
EU514845; UL144: EU514846-EU514890) 
 
Phylogenetic Analysis 
The sequenced ORFs were converted to amino acids using Vector NTI 9 
(Invitrogen).  The predicted mature forms of vCXCL-1 and vCXCL-2 were 
generated with Signal P (www.cbs.dtu.dk/services/SignalP).  Alignments of the 
mature forms of vCXCL-1, vCXCL-2, and UL144 proteins were aligned using 
ClustalX 1.83.  Neighbor-joining phylogenetic trees were generated using 
ClustalX 1.83 with 1000 bootstrap trials.  The generated phylogenetic tree was 
viewed by TreeView (Win32) 1.6.6.  
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Statistical Analysis 
Associations between genotype and whether any symptoms were 
observed were analyzed using Fisher's exact test. For each individual clade, we 
also calculated a 95% confidence interval for the proportion of asymptomatic 
individuals. All analyses were performed using SAS v9.1. 
 
Results 
vCXCL-1s from children with congenital HCMV infection can be 
divided into 11 distinct clades  
To understand whether specific vCXCL-1s correlate with clinical outcomes, 
51 samples were analyzed from 50 congenitally infected children (Table 2).  
TX11 and TX12 were from same child.  Using primers upstream and downstream 
of the UL146 and UL147 genes [158] PCR products were obtained from the 51 
clinical isolates.  Each sample was PCR amplified twice, TA cloned, and two to 
five clones were sequenced.  The accuracy rate was greater than 99.9% 
between the two separate PCR reactions.  For reference sequences, we included 
the previously analyzed strains Toledo, Towne, C952, C954, C956, E760, ML1, 
TB40/E, FS, AL, 6397, KM, RK, Davis, NT, Merlin, and KSG [155, 234] in 
addition to the F strain from Prichard et al [26].  The UL146 ORFs encode 
vCXCL-1 proteins containing between 115-121 amino acids. The mature forms 
without the signal sequence and the reference sequences contain between 93 
and 103 residues that show 5% identity (6 residues) and 8% similarity 
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Table 2. Clinical isolates of congenital CMV infection 
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(9 residues) (Fig. 2).  All sequences were assigned to 11 distinct vCXCL-1 clades 
(Fig. 3).  The intravariability within each clade was less than 6%.  The designated 
genotypic group numbers were assigned according to the 14 UL146 groups 
described by Dolan et al. [234].  No vCXCL-1 sequences were found in groups 3, 
4, and 5 described by Dolan et al. 
If the most distant reference group is removed (NT from Group 4, for 
which we did not assign any samples), the number of 100% consensus residues 
increases from 6 to 11. This includes the CXC chemokine motif and the four 
cysteine residues. This implies that this isolate is a very distant cousin of other 
vCXCL-1s.  This number increases to 12 when all of the reference sequences 
are removed from the analysis.  These conserved residues provide the essential 
structure for all α-chemokines [107].  The vCXCL-1 sequence of TX15 replaces 
the glutamic acid-leucine-arginine (ELR) with asparagine-glycine-arginine (NGR) 
motif, which is similar to the NRG containing chemokine found in the ML1 strain 
[234] (Fig. 2).  Modification of the ELR motif (E → N and L → G) could have 
profound effects on chemokine function as the ELR motif is necessary for 
chemokine activity and receptor binding [237, 238].  To further identify possible 
functional differences that are reflected in their sequences, we clustered the 
groups based on their N-loop regions.  The N-loop region, the residues between 
the second cysteine and the 310-helical turn (approximately 8-10 residues), is 
responsible for receptor engagement and function [36, 106, 107].  Analysis of 
these sequences divides the chemokines into the same 11 groups indicating that 
the N-loop region is mainly responsible for vCXCL-1 variability (Fig. 4).  There is  
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Figure 2. Amino acid alignments of the mature forms of vCXCL-1s from 
clinical isolates.  
vCXCL-1 amino acid sequences from 51 clinical isolates were analyzed. Eighteen symptomatic 
clinical isolates are indicated in bold. The vCXCL-1 sequences from reference strains Toledo, 
Towne, C952, C954, C956, E760, ML1, TB40/E, FS, AL, 6397, KM, RK, Davis, NT, Merlin, and 
KSG (GenBank accession numbers AY681092, AY681095, DQ115733, DQ115734, DQ115735, 
DQ115754, AY446880, AY446866, AY446877, AY446887, AY446870, AY446893, AY446885, AY446868, 
AY446890, AY446894, and AY446889, respectively) plus strain [F] from Prichard et al. (2001) are 
boxed. The ELR motif and N-loop region, which are important in receptor binding and activation, 
are indicated at the top. Residues that are 100% conserved are shaded black and residues that 
are conserved in greater than 80% of the sequences are shaded in gray. Consensus sequences 
with 100%, 90%, and 80% conservations are shown at the bottom. 
 38 
 
 
 
Figure 3. vCXCL-1 phylogenetic analysis. 
The mature forms of vCXCL-1 from 51 clinical isolates with the reference 
sequences (shaded gray) were assembled into a phylogenetic tree using 
ClustalX. Eighteen symptomatic clinical isolates are indicated in bold. Bootstrap 
numbers are shown. Group designations correspond to those used by Dolan et 
al. (2004). 
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Figure 4. Phylogenetic analysis for the N-loop region of vCXCL-1.  
The N-loop regions of vCXCL-1 from 51 clinical isolates with the reference 
sequences (in gray box) were analyzed using ClustalX. Eighteen symptomatic 
clinical isolates are indicated in bold. Bootstrap numbers are shown. Group 
designations correspond to those of the mature forms of UL146 amino acid (Fig. 
2). 
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0% similarity within this region between the different clades.  The fact that there 
is hypervariability within this region implies that these chemokines may have 
different affinities for the chemokine receptors and could trigger different 
downstream signaling and subsequent functions.  Differences in affinity, 
apoptosis, and integrin expression have been noted for chimpanzee CMV 
vCXCL-1 compared to vCXCL-1Tol [239]. 
The variability of vCXCL-1 does not show a definitive correlation between 
specific vCXCL-1 sequences and HCMV sequelae. Overall, there was not a 
statistically significant association between vCXCL-1 clades and symptoms at 
birth (p=0.37).   However, examination of individual clades did reveal three 
clades with an unusually high proportion of asymptomatic children. These were 
group 8 with 7 of 8 (88%) asymptomatic (95% CI: 47% to 100%), group 10 with 3 
of 3 (100%) asymptomatic (95% CI: 29% to 100%) and group 12 with 5 of 6 
(83%) asymptomatic (95% CI: 36% to 100%). 
One isolate, 300016, is assigned to two vCXCL-1 groups (group 1 and 13) 
(Fig. 3).    After resequencing and analyzing 10 clones, these assignments still 
held.  This indicates this child was infected with two different HCMV isolates as 
has been seen in both congenital infections and immune compromised patients 
[27, 240, 241]. 
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vCXCL-2 from children with congenital HCMV infection has limited 
variability 
The UL147 ORF from the same set of clinical isolates encodes vCXCL-2 
proteins comprised of 157–167 amino acids (Fig. 5).  In contrast to the vCXCL-1 
protein the mature form of the vCXCL-2 from the clinical isolates were all 
identical lengths (119 aa).  The mature form of vCXCL-2 shows 87% identity (103 
residues) and an additional 11% similarity (13 residues) overall.  Because of the 
limited variability of UL147 sequences from clinical isolates, the alignment of the 
mature vCXCL-2 proteins falls into a single group.  As previously published, the 
only significant variability within vCXCL-2 occurs in the signal sequence [158], 
which is cleaved during protein maturation.   
 
UL144 sequences fall into three genotypes 
UL144 is a member of the TNF receptor family [164].  Arav-Boger et al showed a 
direct link between specific UL144 genotypes and clinical outcomes [156, 170] 
while others have not [165-169, 242].  In order to establish whether specific 
clades of UL144 are associated with clinical outcomes, 44 UL144 sequences 
from the 51 clinical isolates were amplified and sequenced.  We included the 
sequences of genotypes A, B, C, AB, and AC (GenBank accession numbers 
AF498086-AF498090) as reference sequences.  The UL144 ORF encodes a 
protein of 175–176 amino acids.  The UL144 mature form without the  
 42 
 
 
 
Figure 5. Alignment of the mature forms of vCXCL-2.  
vCXCL-2 sequences from 51 clinical isolates were analyzed. 18 symptomatic 
clinical isolates are indicated in bold. The reference strains Toledo and Towne 
(GenBank accession # AY681092 and AY681095, respectively) were included 
and are boxed. Residues that are 100% conserved are shaded black and 
residues conserved in 80% to 99% of the sequences are shaded grey. The 
consensus residues with 80% conservation are shown at the bottom.  
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signal sequence is between 146–157 residues in length with 60% identity (95 
residues) with an additional 27 similar residues  (Fig. 6).  These UL144 amino 
acid sequences separate the isolates into five major genotypic groups (A, B, C, 
and subgroup AB and AC) (Fig. 7).  Previously, Lurain et al and Arav-Boger et al 
reported the same groupings based on UL144 sequences [166, 170].  We used 
the UL144 classification of Arav-Boger et al for this study.  Bale et al showed 
UL144 variability from 16 congenitally HCMV infected children [165].  They found 
that clinical isolates TX11 and TX12, which were obtained from same child, 
showed different UL144 group designations, group 3 (or B) and group 1 (or A).  
Once again this indicates a child with multiple HCMV infections.  Interestingly, 
our results mapped the UL146 genotypes of these two isolates to the same clade 
(group 11), which were confirmed by two separate PCR amplifications and 
sequencing of five clones each (Fig. 3).  This implies divergence within UL144 
and that the two strains could have evolved under different environmental 
pressures. 
The UL144 protein consists of two cysteine-rich domains (CRD), one 
transmembrane domain (tm), and one cytoplasmic domain (cyto).  Unlike the 
TNFR, UL144 lacks an additional CRD3 region which may explain absence of 
binding to TNF-like ligands [164].  The alignments show that UL144 CRD1, which 
is comprised of 34 residues, shows 50% identity (17 residues) and this 
percentage increases to 71% when similar residues are included.  The CRD2 is 
slightly more conserved.  Of the 36-37 residues, there is 57% identity (21 
residues) and 81% similarity.  BTLA binds to the CRD1 of HVEM, which is  
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Figure 6. UL144 contains highly conserved domains.  
UL144 amino acid sequences from 44 clinical isolates were analyzed. 13 
symptomatic clinical isolates are indicated in bold. Representative sequences 
from genotype groupings A, B, C, AB, and AC (GenBank accession numbers 
AF498086-AF498090) are included as reference sequences and are boxed. 
Residues that are 100% conserved are shaded black and residues that are 
greater than 80% conserved are shaded grey. Consensus sequence with 80% 
conservation across all isolates are shown at the bottom. The cysteine rich 
domains (CRD), the transmembrane region (tm), and cytoplasmic tail (cyto) are 
indicated at the top. 
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Figure 7. UL144 sequences fall into 5 groups.  
The mature forms of UL144 amino acid sequences from 44 clinical isolates were 
analyzed by the ClustalX. 13 symptomatic clinical isolates are indicated in bold. 
Reference sequences are illustrated with grey boxes. Group designations 
correspond to those of Arav-Boger et al (2002).  
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homologous to UL144 CRD1 [236].  As observed in previous studies there is a 
high level of conservation in the transmembrane and cytoplasmic domains of 
UL144 between the different isolates [166, 170].  The variability in the CRD 
regions has been used to infer that the interaction between UL144 and BTLA 
could differ between the different genotypes, leading to differential virus survival 
and/or clinical outcomes.  
Using our clinical samples from congenitally infected children, we show 
that the UL144 genotype does not correlate with HCMV sequelae. Using Fisher’s 
exact test, there was no statistically significant association between UL144 
genotype and symptoms (p-value = 0.45).  Group B in our sample did have 18 of 
23 (78%) asymptomatic (95% CI: 45% to 92%) while groups A and C had lower 
percentages of asymptomatic newborns (Group A= 69% (9/13) and Group 
C=40% (2/5)).  This data indicates that there is no direct correlation between 
UL144 genotypes and symptoms at birth, although the trend of more  
asymptomatic children in group B is similar to the findings of Arav-Boger et al 
[233]. 
 
UL146 genes under immune selection pressure do not mutate  
One explanation for the variability in the UL146 gene is that UL146 
evolves to avoid the immune response.  To address whether the UL146 gene 
accumulates mutations while under immune selection pressure, we studied serial 
HCMV isolates from children who shed HCMV over many years [243].  We 
cloned and sequenced the UL146 ORF from 13 serial isolates from six children 
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from daycare centers in Virginia (Table 3).  For up to three years, there was no 
change in vCXCL-1 (Fig. 8).  However, multiple UL146 sequences were identified 
from sequential isolates from two individuals.  In child 5, isolates 30135 and 
31099 were assigned to group 9 and 8, and in child 6, isolates 23914 and 24864 
were assigned to group 8 and 9, respectively.  In order to confirm these isolates 
resulted from multiple infections and not mutations of the original virus, we 
sequenced the UL144 gene from these same isolates.  The UL144 sequences 
from isolates 23914 and 24864 were assigned to group A and B, respectively.  
This data indicates these children were infected with two different viruses and 
that the UL146 gene did not accumulate multiple mutations leading to 
assignment to a new clade.   
 
Discussion 
There have been several studies addressing the effect of UL146 variation 
on HCMV pathogenesis in immune compromised patients [155, 157-159, 233, 
234]. The UL146 ORF is one of the most variable genes in the HCMV genomes 
following analysis of isolates from AIDS or organ transplant patients [27, 244, 
245].  These studies lead to the classification of UL146 sequences into 14 groups.  
This variability, its role as a chemokine and its absence from lab attenuated 
strains, lead to the hypothesis that this gene could encode a virulence factor.  
Dolan et al, Hassan-Walker et al, and Arav-Boger et al investigated the link 
between specific UL146 clades and symptomatic/asymptomatic congenital 
infections [159, 233, 234].  Arav-Boger et al showed that from 21 clinical isolates  
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Table 3. Serial isolates from Virginia Commonwealth University (VCU) day 
care center  
child No. Isolate ID Sampling Date UL146 Genotype 
24534 12/2/1997 8 
1 
27472 3/9/2000 8 
27568 5/12/2000 10 
27716 7/12/2000 10 2 
29333 8/16/2001 10 
26756 8/25/1999 11 
3 
29524 10/10/2001 11 
29140 6/25/2001 7 
4 
30803 2/20/2003 7 
23914 2/25/1997 8 
5 
24864 4/1/1998 9 
30135 4/25/2002 9 
6 
31099 6/19/2003 8 
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Figure 8. vCXCL-1 does not mutate in long term shedders.  
vCXCL-1 from 13 serial isolates from 6 children for up to 3 years were analyzed. 
A) The alignments shown are from individual children over a span of one to three 
years. Residues that are 100% conserved are shaded black and grey regions 
residues indicate conservative substitutions. B) ClustalX was used for 
phylogenetic analysis of the different isolates.  
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no specific UL146 genotype was associated with disease outcome [233].  
Hassan-Walker et al and Dolan et al showed 4 and 14 genetic groups, 
respectively.  However, due to the small sample size (14 and 7, respectively) 
they could not draw a direct link between genotypes and symptoms [159, 234].   
Even though our study includes a relatively large sample size, we are 
unable to reach statistically significant conclusions about specific UL146 clades 
and symptomatic outcomes. Our results demonstrate that out of the 14 groups, 
11 of the clades did not exhibit a definitive association between UL146 
genotypes and symptoms.  Group 10 contained only asymptomatic children but 
had a sample size of 3.  In group 8, only 1 out of 8 were symptomatic.   From this 
data we can conclude that most of the UL146 genotypes do not correlate with 
symptomatic births and two of these groups (Group 8 and 10) point towards 
asymptomatic outcomes but a statistically significant conclusion is limited 
because of sample size.  
The other gene located within the UL/b’ region, which has homology to the 
TNF receptor and is variable is UL144.  Our UL144 data in this study shows a 
lack of correlation between symptoms and UL144 clades supporting the findings 
of several other studies [156, 165-170, 242].  Only Arav-Boger concluded that 
UL144 is predictive of congenital infection outcomes [156, 170]. The major 
differences between these studies are the sample size and the source of the 
isolates.  Arav-Boger et al suggested that groups A and C are associated with 
more serious outcomes upon analysis of 23 congenitally infected isolates 
comprised of 13 symptomatic neonates and fetuses.  The B genotype was 
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associated with both asymptomatic (10 out of 10) and symptomatic (6 out of 13) 
children and the A and C genotypes were only found in the symptomatic children 
[170].  From this, they concluded that the A and C genotypes are associated with 
symptomatic outcomes.  This group also showed a possible relationship between 
the C genotype and symptomatic diseases in newborns in a study in Italy. They 
showed a statistically significant association between the C genotype and 
termination of pregnancy, while the B genotype did not [156]. This study did 
suffer from enrollment biases as women were enrolled based on a higher risk for 
congenital CMV infections. In contrast, Bale et al examined 51 HCMV isolates 
from 44 patients containing 16 congenitally infected children to conclude that 
UL144 genotype does not correlate with symptoms at birth [165].  Others have 
corroborated the Bale study.  Mao et al analyzed 70 isolates from Chinese 
infants where 58 were from symptomatic children, but only five infants were 
determined to have acquired CMV from congenital infections [167].  An even 
larger Japanese study assessed the UL144 sequences from 74 Japanese HCMV 
isolates where 10 samples were from congenitally infected newborns [168].  
They also reported that UL144 genotype does not correlate with symptoms.  
Analyzing HCMV congenitally infected fetuses, Picone et al concluded that there 
was no correlation between severity of infection and UL144 genotype [242].   All 
of these studies divided the UL144 genotypes into three major groups: 1, 2, and 
3 (or A, C, and B, respectively) and did not find a statistically significant 
relationship between these genetic groups and specific clinical symptoms at birth.  
In our study, 23 of 44 samples had the B UL144 genotype.  Of these, 5 of 23 
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infants were symptomatic while 18 were asymptomatic.  In contrast to the study 
of Arav-Boger, we observed that both A and C clades contain both asymptomatic 
and symptomatic children (Fig. 7).  Therefore, our analysis of the UL144 
sequences agrees with previous findings of Bale et al.  
Because of its high variability, UL146 sequences can be used as an 
indicator of multiple HCMV infections. Multiple HCMV infections could be due to 
either incomplete protection after HCMV infection or coinfection simultaneously 
with different strains of HCMV. Multiple infections have been found in both 
congenitally infected patients [233], renal transplant patients [155],  bone marrow 
transplant patients [155], and AIDS patients [234].  In immunocompetent children, 
Bale et al studied 11 serial isolates from five children for up to 2.5 years and 
found multiple sequences [165]. Based on the genetic stability of UL146 
sequence over time, multiple sequences are not due to random mutations.  
Therefore the multiple sequences were due to coinfection with another strain of 
HCMV.  We have also found multiple sequences from children in daycare (Fig. 
8A) indicating that coinfections with multiple strains of HCMV are possible. 
Since UL146 and UL144 genes are variable, many studies have 
addressed the stability of UL146 or UL144 genotype upon serial isolation over 
many years [155, 157, 159, 168, 170, 234].   Lurain et al studied various organ 
transplant recipients for up to 5 years with no changes in UL146 sequence [155]. 
Both in vitro [155] and in immune compromised hosts, UL146 did not mutate over 
time [159].  A possible explanation of UL146 and UL144 hypervariability could be 
due to immune selection pressure within the host.   Our study (Fig. 8) and Bale et 
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al analyzed immunocompetent children shedding virus over many years.  This 
would have allowed for vigorous immune selection compared to the 
transplantation studies where the host is immune suppressed and are often 
treated with anti-CMV drugs.  Immune selection could select for mutated, 
secreted vCXCL-1 protein that is recognized as foreign, because it is only ~20-
30% homologous to host chemokines.  Interestingly, Lurain et al showed no 
variation in UL146 sequences even when different patients received organs from 
the same donor.  These organs contained the same strain of HCMV as the donor 
but were transplanted into different hosts, which could mount different immune 
responses [155].  This shows the stability of UL146 over time and in different 
immunological settings from different individuals.   
Most immune competent individuals shed HCMV for about 9-12 months 
after acquisition.  In contrast, primary CMV infection of neonates and infants 
results in continuous viral shedding into the urine and saliva for several years 
[246-248].  Our data are unique in that our samples were isolated from healthy 
children (i.e. not immunocompromised).  If immune selection drives UL146 
variation, our analysis should identify it.  Our data from healthy children also 
agrees with the studies from immunocompromised patients. We found 2 cases of 
coinfection, which fell into group 8 and 9, but no sequence changes were 
detected during two years, indicating that virus maintains its genetic integrity 
under healthy immune defense.  If mutations are not occurring in this time frame, 
how and why are these genes so variable?  One possibility is that changes in the 
genes accumulated during HCMVs’ co-evolution with humans.  The gradual 
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changes in UL146 and UL144 provide an evolutionary advantage, which only 
becomes dominant over millennia.   
In conclusion, this study shows that specific UL146 and UL144 genotypes 
do not correlate with the sequelae of congenital infection.  We also show that 
some children in daycare are infected with multiple strains of HCMV and that 
their HCMV UL146 genotypes do not change over several years.  
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Chapter 4 
POLYMORPHISMS IN HCMV VIRAL CHEMOKINE, VCXCL-1, 
ELICIT DIFFERENTIAL ACTIVATION 
 
 
Abstract 
The human cytomegalovirus (HCMV) UL146-encoded viral chemokine, 
vCXCL-1, is hypervariable.  In our previous analysis of clinical isolates from 
congenitally infected infants, we found 11 distinct vCXCL-1 genotypic clades.  In 
these clades, the N-loop region, which is important for receptor-binding varied.  
One isolate also contained a modified ELR motif, which is vital for binding to 
CXCR1 and CXCR2 receptors.  In this study, we produced and purified 
representative vCXCL-1 proteins from each of the 11 clades using a baculovirus 
protein expression system.  We measured vCXCL-1’s affinity for either CXCR1 or 
CXCR2 using competition binding assays.  All vCXCL-1s bound to CXCR2 albeit 
with different affinities.  Interestingly, we found a trend that vCXCL-1s with high 
affinity for CXCR2 receptors also bind CXCR1.  We also examined functional 
differences between the vCXCL-1s using chemotaxis, integrin activation, and 
calcium mobilization assays on human neutrophils.  All vCXCL-1s were able to 
activate human neutrophils.  However, the potency of the vCXCL-1s to induce 
chemotaxis of neutrophils varied.  Moreover, the vCXCL-1s varied in their ability 
to induce CCL22 production, which did not correlate with chemotaxis potencies.  
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Our data suggest that the vCXCL-1 polymorphisms elicit different binding 
affinities, receptor usage, and differential cellular activation, which potentially 
contribute to HCMV pathogenesis. 
 
 
Introduction 
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that is well 
adapted to modulate host immune responses [113, 249].  HCMV contains genes 
for immune evasion that could function to increase viral survival, dissemination, 
or may contribute to pathogenesis [143, 250, 251].  There are a large number of 
open reading frames (~62) called the UL/b’ region in HCMV that are non-
essential for virus replication in vitro but may have a role in immune evasion in 
vivo [25, 245].  Among the UL/b’ open reading frames (ORFs), UL146 and UL147 
genes have limited homology to CXC chemokines [25].  The UL146 ORF from 
the Toledo strain of HCMV called vCXCL-1Tol has been shown to produce a 
functional CXC chemokine [143].  vCXCL-1Tol binds to CXCR1 and CXCR2, 
induces neutrophil chemotaxis and calcium mobilization [154].  These data 
suggest that vCXCL-1s produced from CMV-infected endothelial cells recruit 
neutrophils and contribute to viral dissemination [143, 252]. Sequencing of the 
HCMV genomes and the UL146 gene from numerous clinical isolates [27, 240, 
241, 244, 245, 253] showed that the UL146 gene is one of the most variable 
genes in the entire HCMV genome [27].  
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vCXCL-1s are members of the chemokine family.  Chemokines are small 
chemoattractant cytokines between 70-130 amino acids in length.  The two major 
families of chemokines (CC and CXC) contain four conserved cysteine residues 
that contribute to the overall structure.  Whether an amino acid separates the 
amino terminal cysteines is used for dividing chemokines into the CXC or CC 
families.  The N-terminus preceding the first cysteine is an important region for 
receptor binding and activation [30, 96].  The Glu-Leu-Arg (ELR) motif found in 
CXC chemokines is a critical motif for CXCR1 and/or CXCR2 receptor 
recognition and activation [102, 103].  Introduction of an ELR motif into the non-
ELR CXC chemokine CXCL4 (PF4) converted it into a neutrophil attractant and 
activator [34], although another non-ELR CXC chemokine, CXCL10 (IP-10), 
required additional modifications to become a fully functional protein on human 
neutrophils [104].  Following the second cysteine is a flexible N-loop of 
approximately ten residues.  The N-loop is responsible for receptor engagement 
and function [30, 35, 96, 104].  Skelton et al. showed that CXCL8 and CXCR1 N-
terminus fragment, CXCR1-p1, interact along the ELR and N-loop motifs of 
CXCL8 [105].  Further, Lowman et al. demonstrated that CXCL1 (Gro-α) could be 
altered to bind both CXCR1 and CXCR2 when the N-loop region of CXCL8 (IL-8) 
was swapped into CXCL1 [96].  These data indicate that the ELR motif is 
necessary for receptor recognition and the N-loop region controls specificity for 
CXCR1 over CXCR2.  
Previously, we sequenced the UL146 gene from congenitally HCMV 
infected clinical isolates [160].  We found 11 clades of vCXCL-1 including one 
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non-ELR CXC chemokine, vCXCL-1TX15.  Furthermore, analysis of the N-loop 
divides the chemokines into the same 11 clades, indicating that the N-loop region 
is mainly responsible for vCXCL-1 variability [160].  Although the genetic 
variability of vCXCL-1 did not show a definite correlation with clinical symptoms, 
this hypervariability within the N-loop region suggests that these chemokines 
may have different affinities, receptor usage, and trigger different downstream 
signaling and functions.  For example, eotaxin (CCL11) induces eosinophil 
migration exclusively via CCR3.  CCR3 is known to be a promiscuous chemokine 
receptor, responsive to more than a dozen different ligands [254, 255].  Eotaxin-2 
and eotaxin-3 bear less than 40% identity to eotaxin at the amino acid level (i.e. 
eotaxin vs. eotaxin-2 (39%); eotaxin-2 vs. eotaxin-3 (33%)), yet they also bind 
and function through CCR3.  While eotaxin and eotaxin-2 bound equally, eotaxin-
3 showed ~10-fold lower affinity than eotaxin [256].  Eotaxin-3 was less potent 
than eotaxin in eosinophil chemotaxis [257] while eotaxin-2 showed  a similar 
potency to eotaxin [258].  In order to address functional variability of the vCXCL-
1s, we generated recombinant vCXCL-1s from each clade and performed 
competition-binding assays and functional assays to assess how vCXCL-1 
variability affects function.  
 
Materials and methods 
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Cells and clinical isolates 
Insect cells SF9 were purchased from Gibco and Hi5 cellls from Cellgro.  
HEK293 cells were a gift from Dr. Cynthia Peterson’s lab (University of 
Tennessee).  Human myelomonocytic HL-60 T2 cell transfectants over-
expressing CXCR2 were a gift from Dr. Ann Richmond (Vanderbilt University).  
The 51 clinical isolates were provided by Dr. James Bale (University of Utah 
School of Medicine) and Dr. Gail J. Demmler (Texas Children's Hospital) as 
described previously [160]. 
 
Neutrophil isolation 
Peripheral blood neutrophils (PBN) were isolated from EDTA-treated 
blood from healthy human volunteers using dextran sedimentation and density 
gradient centrifugation as previously described [259].  Erythrocytes were 
removed with hypotonic lysis in 0.2% NaCl.  After removal neutrophils were 
resuspended in the buffers for the individual assays.  Viable neutrophils were 
quantified with trypan blue exclusion using a hemacytometer. The use of human 
subjects has been approved by the University of Tennessee Institutional Review 
Board (IRB# 6476B). 
 
Production of recombinant vCXCL-1s 
The vCXCL-1 gene, UL146, was PCR amplified from HCMV DNA of each 
of the 11 clades from a representative clinical isolate and cloned into the 
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baculovirus transfer plasmid 1392 (Invitrogen), which contains homologous 
regions for recombination into the baculovirus genome.  PCR primers were 
designed to include the open reading frame (ORF) and included an additional 2-4 
glycines and six histidines on the carboxyl terminus of the proteins for 
purification.  For the generation of baculoviruses, SF9 cells were transfected with 
the 1392/UL146 ORF plasmid construct and Sapphire linearized baculovirus 
DNA (Orbigen) according to the manufacturer’s instructions.  Recombinant 
baculovirus containing the UL146 gene was titrated and used to infect Hi5 cells 
for optimum protein expression.  48 hrs after infection, cells and supernatants 
were harvested.  Recombinant proteins were isolated from the supernatants 
using Ni-NTA agarose beads (Qiagen) and resuspended in PBS.  Protein 
concentration was quantified using Coomassie blue staining of SDS-PAGE gel 
using lysozyme as a standard.  Quantity One software (Bio-Rad) was used for 
protein quantification.  
 
Receptor binding analysis 
The ability of vCXCL-1s to compete for binding to either CXCR1 or 
CXCR2 was evaluated as previously described [143].  Briefly, 1-3x105 HEK293 
cells over-expressing CXCR1 or CXCR2 were incubated with 0.2nM 125I-labeled 
CXCL8 (Perkin Elmer) and increasing concentrations of unlabeled chemokines.  
Cells were collected via a 96-well 0.45 mm Durapore membrane (Millipore) filter 
format on a vacuum manifold, washed twice, and bound radioactivity was 
 61 
measured with liquid scintillation counting.  The competition curves were plotted 
and 50% effective concentration (EC50) were determined using GraphPad Prism. 
 
Intracellular calcium mobilization assays 
Release of calcium from intracellular stores was determined on freshly 
isolated PBN resuspended in PBS.  Cells were loaded with 3 µg/ml Indo-1-AM 
(Molecular Probes) for 60 min at 37 °C.  Cells were washed with PBS and diluted 
to 1×106 cells/ml in Hanks' balanced salt solution (HBSS) containing Ca2+ and 
Mg2+ and 1% FBS (Hyclone).  Chemokines were added to 2 ml of cells at a final 
concentration of 100 nM.  All host chemokines were purchased from Peprotech 
(Rocky Hill, NJ) and endotoxin levels were less than 0.1 ng per µg (1 EU/µg).  
Calcium flux was measured using a Photon Technology International 
Spectrophotometer (New Jersey) at an excitation of 350 nm and FeliX32 
software for analysis.  Relative intracellular calcium levels were expressed as the 
ratio of emissions at 490 nm / 400 nm.  
 
β2 integrins staining 
1×106 PBN cells were resuspended in RPMI-1640 (Biowhittaker) with 1% 
FBS and exposed to 100 nM of chemokines for 2 h at 37 °C.  Cells were washed 
with PBS and blocked with 1% goat serum.  PBN were incubated with 
fluorescently conjugated CD11a, CD11b, and CD11c antibodies (Caltag) on ice 
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for 30 min. and fixed with 4% paraformaldehyde.  Cells were analyzed with flow 
cytometry (FacsCalibur, BD Bioscience).  
 
Human PBN chemotaxis assays 
Chemotaxis assays were performed on freshly isolated human PBN 
resuspended in HBSS with 0.1% BSA and 10 mM HEPES.  Assays were 
performed in triplicate in 96-well chemotaxis plates.  20 µl of chemokines were 
loaded at varying concentrations (0, 1, 10, 100, and 500 nM) into the lower well 
of the modified Boyden chamber (Neuroprobe) fitted with a 5 µm filter.  1×106 
PBN in 30 µl were added to the upper well.  The cells were incubated for 3 h at 
37 °C.  Migration of PBN was measured by direct counting of migrated cells into 
the lower chamber.  The chemotactic index was calculated as the number of 
migrated cells in the presence of chemokine divided by the number of migrated 
cells with buffer only. 
 
Quantitative real-time PCR of CCL22 expression 
HL-60 T2 cells over-expressing CXCR2 were differentiated for 7 days with 
1.3% DMSO prior to chemokine treatment.  Media was exchanged to HBSS and 
incubated with viral chemokines at a final concentration of 100 nM for 4 h at 37 
°C.  Total RNA was isolated with Tri-Reagent (Sigma) and reverse transcribed by 
the ProtoScript M-MuLV first strand cDNA synthesis kit (NEB).  Real-time PCR 
was performed using iQ5 Real-Time PCR Detection System (Bio-Rad) with a 
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reaction mixture volume of 25 µl containing SYBR green (NEB DyNAmo SYBR 
green qPCR kit), 300 nM of each primer, and ~25ug of cDNA.  Primers for 
CCL22 were purchased from SABiosciences (Cat # PPH00697E).  The reaction 
conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C 
for 60 s.  Data analysis used iQ5 Optical System Software (Bio-Rad).  The 
relative gene expression levels were calculated as fold changes using the 
formula Ratio = 2−ΔΔCT, where ΔCTtarget or reference = threshold cycle (CT) of the 
control gene (ACT1) − CT of the target gene (CCL22), and ΔΔCT = ΔCTreference − 
ΔCTtarget [260].  The housekeeping gene encoding actin (ACT1) was used as a 
reference control.  
 
 
Results 
Amino acid sequence alignment  
Previously we sequenced the UL146 gene from 51 clinical isolates and 
showed that it comprised 11 genetic clades [160].  From 11 clades, 
representative isolates were selected and aligned with vCXCL1 from the Toledo 
strain (Fig. 9A).  The percent identities of the vCXCL-1s ranged from 23.7 – 
61.2% with 11 conserved amino acids: including the R of ELR motif, the four 
cysteines, a glycine at position 21, two prolines at positions 32 and 87, a leucine 
at position 56, a histidine at position 60, and a tryptophan at position 65 (Fig. 9A).  
The Gly21 generates a single-turn 310 helix that finishes the N-loop region.  The  
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Figure 9. Amino acid alignment and recombinant vCXCL-1 production.  
(A) Amino acid alignment of the mature forms of vCXCL-1s and host chemokines 
(CXCL1 and CXCL8). Seven amino acids are conserved including four cysteines. 
The ELR motif is conserved except for vCXCL-1TX15. The variable N-loop region 
is located after second cysteine. (B) Recombinant vCXCL-1s production in 
baculovirus protein expression system. 6His-tagged protein eluted from nickel 
beads was run on a 15% SDS PAGE gel and stained with Coomassie blue.  
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Pro32 is located in the 30s-loop between the β1-sheet and β2-sheet.  Previously, 
the Gly31-Pro32 motif in CXCL8 was shown to be essential for determining the 
structure of the 30-35 region and possibly the 5-35 disulfide bond [29, 97, 104].  
The Trp65 and Pro87 are in the C-terminal α-helix, which is followed by His60.  
Furthermore, Leu25 and Val27 in CXCL8 that creates a hydrophobic 
environment for dimer formation was not conserved in the vCXCL-1s [261, 262].  
Also, mutation of Leu25 to tyrosine introduces monocyte chemoattractant activity 
into CXCL8 [263].  Therefore, different β1-sheet amino acid formation can 
possibly contribute to determining cell type selectivity via selective chemokine 
receptor binding.  
The mature forms of the viral chemokines, without the signal sequences, 
contain between 93-98 residues; whereas human chemokines, such as CXCL1 
(Gro-α) or CXCL8 (IL-8), contain 70-71 residues.  What affect these additional 20 
residues of vCXCL-1s have on function is unknown.  However, it has been 
shown that glycosaminoglycans (GAGs) can bind to the C-terminal α-helix of 
CXCL8 enhancing chemokine activity on neutrophils [264].  When vCXCL-1s are 
compared to human chemokines, the scope of the percent identities was lowered 
to 16.8% with 7 conserved residues: including the R of ELR motif, the four 
cysteines, a proline at position 32, and a leucine at position 56.  The ELR motif 
was conserved except vCXCL-1TX15 which replaces ELR with an Asn-Gly-Arg 
(NGR) motif.  Single amino acid substitutions in this motif showed that all three 
residues are sensitive to modification although the arginine is critically important 
for CXCL8 function [34, 35].  Therefore, the modified ELR motif of vCXCL-1TX15 
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could have profound effects on chemokine function or receptor binding [102, 
103].  The variable N-loop region that is mainly responsible for vCXCL-1 
variability is followed by the second cysteine [160].  Taken together, from the 
high degree of variability in the N-loop, C-terminus, and even the ELR motif, we 
hypothesized that there would be differences in function and even receptor 
usage based on the modified ELR motif. 
 
vCXCL-1 production using the baculovirus expression system 
In order to address functional differences between the vCXCL-1s, we 
generated recombinant vCXCL-1s using the baculovirus protein expression 
system.  Baculovirus expression provides mammalian signal-sequence cleavage, 
generates eukaryotic glycosylation patterns and protein folding.  vCXCL-1s were 
6 His-tagged and purified using Ni-NTA agarose beads.  A Coomassie blue stain 
of the isolated proteins is shown in Fig. 9B.  The sizes ranged from 
approximately 11 kDa to 15 kDa.  The actual molecular weights of vCXCL-1s 
were confirmed by Matrix-assisted laser desorption/ionization (MALDI) (Table 4).  
 
vCXCL-1s vary in their affinities for CXCR1 or CXCR2  
The conserved ELR motif suggests that the viral chemokines bind to 
CXCR1 and/or CXCR2.  However, the hypervariable N-loop binding region of the 
vCXCL1s and non-ELR motif of vCXCL-1TX15 could result in differences in 
receptor binding affinity.  To test this possibility, competition-binding assays were  
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Table 4. Molecular weight of vCXCL-1s by Matrix-assisted laser 
desorption/ionization (MALDI) analysis 
Chemokine MW by MALDI 
Toledo 14137 
E760 11077 
TX15 12032 
Towne 11960 
C954 11961 
102410 11880 
100751 11853 
TX11 11157 
TX24 13036 
C956 12912 
C952 11959 
 68 
used to evaluate the ability of vCXCL-1s to compete for binding to human 
CXCR1 and/or CXCR2.  All vCXCL-1s were able to compete with [125I]-CXCL8 
for binding to CXCR2.  50% effective concentrations (EC50) of vCXCL-1s were 
higher than CXCL8 (EC50 = 1.1 nM) (Fig. 10A).  This indicates that most vCXCL-
1s bind to CXCR2 with a lower affinity than CXCL8.  Among them, three vCXCL-
1s showed a high level of affinity for CXCR2 (vCXCL-1C952 EC50 = 3.5 nM, 
vCXCL-1E760 EC50 = 3.8 nM, and vCXCL-1Tol EC50 = 5.1 nM).  Interestingly, the 
non-ELR CXC chemokine, vCXCL-1TX15, still bound to CXCR2 albeit with very 
reduced affinity (EC50 > 131.4 nM).  We also examined vCXCL-1 binding affinity 
to CXCR1 to evaluate an idea of whether these chemokines mimic CXCL1, 
which binds only to CXCR2, or CXCL8, which binds to both CXCR1 and CXCR2 
(Fig. 10B).  Although the binding affinities were very low, those with high affinity 
binding to CXCR2 also showed binding to CXCR1 while the others demonstrated 
no binding (vCXCL-1Tol EC50 > 46.7 nM, vCXCL-1C952 EC50 > 97.7 nM, vCXCL-
1E760 EC50 > 143.3 nM).  This points to a trend that vCXCL-1s with high affinity to 
CXCR2 receptors can also bind CXCR1. 
 
vCXCL-1s stimulate calcium release in human PBN 
Release of intracellular calcium is a common indicator of chemokine 
activation of PBNs [143, 144].  vCXCL-1s were added to 2 ml of freshly isolated 
human PBN to a final concentration of 100 nM.  All vCXCL-1s showed similar 
activation potential (Fig. 11) demonstrating that recombinant vCXCL-1s are 
capable of inducing cellular activation of human PBNs and any differences in  
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Figure 10. vCXCL-1s display variable affinities for CXCR1 and CXCR2.  
(A) vCXCL-1s bind to CXCR2 with varying affinities. Representative vCXCL-1s 
are shown. HEK293 cells stably expressing only CXCR2 were incubated with a 
constant amount (0.2nM) of [125I]-CXCL8 and increasing amounts of unlabeled 
chemokines as cold competitor. (B) Three vCXCL-1s bound to CXCR1 with 
various binding affinities whereas other vCXCL-1s did not bind (>1000).  (C) The 
table summarizes the calculated EC50 values of all vCXCL-1s binding to CXCR1 
and CXCR2 (nanomolar (nM)). vCXCL-1s that do not displace greater then 90% 
of total counts are indicated with a > sign; therefore we are unable to calculate 
accurate EC50 values with confidence. The data was analyzed in Prism 4.0. This 
is combined data of three experiments. 
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Figure 11. vCXCL-1s, regardless of affinity, mobilize intracellular calcium.  
Recombinant vCXCL-1s have similar activation thresholds as host chemokines. 
Changes in fluorescence were measured over time after exposure of human 
PBN to 100nM of vCXCL-1s. Arrows indicate the time of addition of the 
chemokine. Data is representative of three experiments. 
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CXCR2 affinities do not affect calcium mobilization.  Interestingly, 500 nM of the 
non-ELR CXC chemokine, vCXCL-1TX15, did not show calcium mobilization in the 
presence of 1 uM the CXCR2-specific inhibitor SB225002 while reduced 
activation was observed when 100 nM CXCL8 was treated in the presence of the 
inhibitor.  This data indicates that even though vCXCL-1TX15 has a non-ELR CXC 
motif, it still activates PBNs exclusively through CXCR2 (data not shown). 
 
vCXCL-1s upregulate CD11b and CD11c on the surface of PBN 
β2 integrins consist of an α component, such as CD11a, CD11b, and 
CD11c, and a β component, CD18.  They are present on circulating leukocytes 
and mediate leukocyte adhesion and transmigration across the endothelium 
[265].  Previous studies demonstrated the ability of CXCL8 to upregulate CD11b 
expression [266].  Moreover, vCXCL-1Tol and a viral chemokine from chimpanzee 
CMV (vCXCL-1CCMV) also increased CD11b and CD11c expression on the cell 
surface of PBNs [144].  We tested the ability of vCXCL-1s stimulation to alter 
surface expression of these receptors on PBNs.  Exposure of human PBNs to 
vCXCL-1s resulted in no change in the level of CD11a expressed on the cell 
surface (Fig. 12).  However, CD11b and CD11c levels increased upon exposure 
to vCXCL-1s.  The percent changes in the mean fluorescent intensity of CD11b 
were 57-91.2 %, which were similar to CXCL1 (82.4 %) but less than CXCL8 
(142.6 %).  Likewise, the percent changes of CD11c were 34.9-55.3 %, which 
were similar to CXCL1 (42.8 %) but still less than CXCL8 (80.3 %).  These 
results imply that the viral chemokines selectively induce adhesion molecule  
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Figure 12. vCXCL-1s differentially increase β2 integrin expression on the 
surface of neutrophils.  
(A) Human PBN were incubated in the presence of 100 nM of different vCXCL-1s 
and labeled with fluorescently-conjugated antibodies against CD11a, CD11b, and 
CD11c. Representative vCXCL-1s are shown. The shaded curve represents 
expression levels of unstimulated neutrophils. (B) The table summarizes the flow 
cytometry data and is expressed as percent change in the mean fluorescent 
intensity compared to non-stimulated PBNs. This is representative experiment of 
three experiments. 
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upregulation, but there were no significant differences in expression levels 
between different viral chemokines.   
 
vCXCL-1s induce differential migration of human PBN 
CXCL8 and vCXCL-1Tol are potent chemoattractants of neutrophils [102, 
143].  The ability of the HCMVs to alter PBN migration could have a profound 
effect on HCMV dissemination and subsequent pathogenesis.  In order to 
address whether vCXCL-1 variation results in chemotaxis of PBNs, each 
chemokine was used as a chemoattractant in a modified Boyden chamber assay.  
vCXCL-1s showed different potencies in induction of neutrophil migration (Fig. 
13). We categorized chemokines as low, intermediate and high responders 
based on a ten-fold increase above random migration.  vCXCL-1C954 showed the 
highest chemotactic index among vCXCL-1s while the non-ELR CXC chemokine, 
vCXCL-1TX15, was a low responder.  Interestingly, the differences in potency of 
neutrophil migration did not correlate with the differences in affinity for CXCR2 or 
CXCR1 binding (Fig. 10). 
 
vCXCL-1s differentially induce secondary chemokine production 
(CCL22) 
In order to examine secondary effects of vCXCL-1 exposure, the neutrophil-like 
cell line, HL60T2, was stimulated with vCXCL-1Tol, host human chemokine 
CXCL1, or PBS control and the change in transcription levels were measured  
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Figure 13. vCXCL-1s induce variable chemotaxis patterns of human 
neutrophils.  
Chemotaxis assays were performed by loading neutrophils into the upper 
chamber of a 96-well plate fitted with a 5 µm filter with increasing amounts of 
chemokine loaded in the lower chamber (1, 10, 100, and 500nM). Results are 
reported as a chemotactic index of the number of cells migrated divided by the 
random migration ±S.D. Low responders are 20 fold greater than background. 
Intermediate responders are 20-200 fold greater. High responders are more than 
200 fold greater. Data is representative from 10 experiments. 
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using Affymetrix whole human genome array.  One of the genes that was up 
regulated upon exposure to either host or viral chemokines was CCL22 
(macrophage derived chemokine (MDC) (data not shown)). CCL22 recruits 
multiple immune cells, such as monocytes, dendritic cells, NK cells, and the Th2 
subset of T cells [267].  Because HCMV can productively infect macrophages 
and dendritic cells and an increase in Th2 responses will down-regulate Th1 
responses, inducing CCL22 could increase HCMV dissemination while 
diminishing CTL responses [118, 119].  We measured mRNA expression levels 
of CCL22 upon exposure to the different vCXCL-1s (Fig. 14).  We found that 
vCXCL-1s differentially induce CCL22 production in vitro.  For example, vCXCL-
1Tol showed the highest induction of CCL22 similar to or slightly higher than host 
CXCL1, whereas the strains of Towne, TX15, 100751, 102410, and C954 did not 
induce CCL22 expression.  Interestingly, CCL22 induction correlated with affinity, 
unlike calcium flux or integrin expression (Fig. 10). vCXCL-1C952, vCXCL-1E760, 
and vCXCL-1Tol showed high affinity for CXCR2 and the highest CCL22 
production.  These patterns, however, do not correlate with their chemotaxis 
profiles.  This shows the complexity of signaling for the different phenotypic 
readouts following chemokine exposure and how these chemokines can 
functionally select different pathways. 
 
Discussion 
In order to investigate the relationship between the hypervariable vCXCL-1s and 
clinical outcomes, we previously cloned and analyzed UL146 ORF from  
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Figure 14. Secondary chemokine production (CCL22) various upon vCXCL-
1 stimulation.  
Neutrophil-like HL-60 T2 cells over-expressing CXCR2 were incubated in the 
presence of 100 nM of different vCXCL-1s. Total RNA was extracted and reverse 
transcribed for real time RT-PCR.  A ratio of 1, indicated with a dashed line, 
means no change in expression compared to the negative control with no 
chemokine treatment.  This is representative data from three experiments 
using separately stimulated HL-60 T2s each time. 
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congenitally CMV infected children [160].  We did not find a statistical correlation 
between a specific UL146 genotype and congenital infection outcome, which 
perhaps was due to the limited sample size.  However there were specific clades 
that showed a tendency toward asymptomatic outcomes.  This led us to the 
current investigation of chemokine function to address whether specific vCXCL-1 
clades have distinct functions or at least different levels of activation.  Alignment 
of the mature vCXCL-1s showed the highly conserved ELR motif and placement 
of the conserved cysteines, whereas the N-loop region was hypervariable with 
very little homology (Fig. 9).  Structure-function studies on chemokine and 
chemokine receptor interactions have suggested a two-site binding model [101, 
268, 269].  This model introduces two interaction sites: the N-loop of the 
chemokine to the N-terminus of receptor (Site-I)  and the N-terminus including 
the ELR motif to the extracellular/transmembrane part of the receptor (Site-II).  
Site-I binding serves as an initial docking step, and then Site-II interaction 
induces conformational changes in receptor transmembrane helices that allow 
signaling of cellular function [270].  We have shown that two additional viral 
chemokines (vCXCL-1C952 and vCXCL-1E760) bind to CXCR1 and this correlated 
with high affinity binding to CXCR2.  The evolutionary advantage of binding to 
CXCR1 could be an induction of neutrophilic responses, such as increased 
chemotaxis, cytokine production or ”functionally selective” cellular responses.  
There are two nonexclusive models for the role of viral chemokines in 
HCMV dissemination.  One model is the neutrophil shuttle model. This model 
proposes that the neutrophil is the main vehicle for HCMV dissemination [271].  It 
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has been reported that HCMV abortively infects neutrophils during neutrophil 
transendothelial migration across infected endothelium and subsequently 
transmits HCMV to fibroblasts [252, 272].  This would allow HCMV to infect the 
surrounding tissues or different cell types.  The guinea pig CMV (GPCMV) MIP 
homolog functions through the CCR1 receptor and appears to play a role in viral 
dissemination in vivo [149, 273]. Furthermore, viral-related inflammation also 
likely contributes to cytomegalovirus-related inner ear injury (auditory pathology) 
[274]. We analyzed the cell activation level and induction of adhesion molecules 
upon vCXCL-1 treatment, which could affect neutrophil diapedesis from the 
vasculature and subsequent cell-mediated viral dissemination.  In this study, 
although the binding affinities to CXCR2 and/or CXCR1 were variable, all 
vCXCL-1s were capable of inducing intracellular calcium mobilization in PBNs 
(Fig. 11) and upregulating β2 integrins on the surface of PBNs to similar levels to 
human CXCL1 (Fig. 12).  Chemotaxis of circulating neutrophils is dependent on 
adhesion to and extravasation across the endothelium.  Therefore, we conclude 
that vCXCL-1s increase PBN contact with the endothelium and could then use 
PBN as a vehicle for dissemination. Interestingly, albeit all tested vCXCL-1s 
showed similar activation patterns in both calcium flux and β2 integrin assays, 
they have different potencies to recruit human PBN (Fig. 13).  This response was 
independent of receptor binding affinity.  For example, vCXCL-1C952 has high 
affinity but low chemotaxis and vCXCL-1C954 showed low affinity but high 
chemotaxis.  This leads us to conclude that different receptor binding affinities do 
not directly correlate with subsequent PBN activation, integrin upregulation or 
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chemotaxis pattern.  This has recently been shown in a mutagenic study of 
CXCL8 where mutations of the CXC motif diminished affinity while not affecting 
function [268]. 
Another model for the relationship between the viral chemokine and 
neutrophil is the neutrophil amplifier model.  The focus of this model is more of 
the downstream effects of neutrophil activation.  This model proposes that 
vCXCL-1 leads to exocytosis of neutrophilic granules or induces expression of 
specific cytokines or chemokines that then affect the next wave of the 
inflammatory response that would then contribute to HCMV dissemination.  For 
example, macrophages and dendritic cells would provide better targets for HCMV 
because HCMV can productively infect these cells [275-277] while infection of 
PBNs is abortive [272].  Moreover, HCMV infection promotes monocyte-to-
macrophage differentiation as a strategy to promote viral replication [277].  At the 
same time, secretion of chemokines or cytokines from the infiltrating cells could 
also alter the immune response.  This has been proposed for the Kaposi 
sarcoma-associated herpes virus (KSHV)-encoded CC chemokine vMIP-III.  It is 
a CCR4 agonist that selectively attracts Th2 cells [278].  Since the host response 
to viral infection is mainly Th1-mediated [279], the recruitment of Th2 cells and 
down-regulation of Th1 responses would be beneficial for HCMV [118, 119].  
In order to examine the amplifier model, we measured CCL22 levels 
following vCXCL-1 exposure (Fig. 14). CCL22 is a potent chemoattractant for 
monocytes, dendritic cells, NK cells, and the Th2 cells [267].  HCMV induction of 
CCL22 could lead to an influx of cells that could then be used as a vehicle for 
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dissemination and/or alter the Th status allowing for delayed viral clearance.  
Analysis of CCL22 transcript levels found that vCXCL-1s can induce CCL22 
production (Fig. 14).  vCXCL-1Tol, vCXCL-1E760, and vCXCL-1C952 showed high 
induction of CCL22 similar to CXCL1.  Interestingly, CCL22 levels paralleled 
vCXCL-1 affinity for CXCR2 and ability to bind to CXCR1.  In the case of 
secondary chemokine secretion, affinity does correlate with CCL22 production.  
Unlike CCL22 induction, calcium flux, integrin expression and chemotaxis 
patterns did not correspond with chemokine receptor affinity.  For example, 
vCXCL-1Tol, vCXCL-1C952, and vCXCL-1E760, the intermediate responders in 
chemotaxis, showed high binding affinities to CXCR2 (and the ability to bind to 
CXCR1) and high levels of CCL22 induction.  Conversely, vCXCL-1C954, a high 
responder in chemotaxis, showed low binding affinity to CXCR2 and low 
induction of CCL22.  vCXCL-1TX24 also showed similar results to vCXCL-1C954.  
Only vCXCL-1TX15, a non-ELR CXC chemokine, showed a correlation between 
these assays: low binding affinity, low response in chemotaxis, and no change in 
CCL22 induction.  But vCXCL-1TX15 also showed similar calcium flux and integrin 
upregulation patterns as well other vCXCL-1s. It is possible that vCXCL-1TX15 has 
different functions in vivo through calcium flux and integrin induction without 
complete neutrophil activation.  
Discrepancy in the results between binding affinity, chemotaxis, and 
CCL22 induction profiles could be explained through functional selectivity of a 
receptor [72, 280].  G protein-coupled receptors (GPCR) are allosteric proteins 
that are capable of adopting different conformations, which can lead to changes 
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in downstream effector proteins such as the G-proteins or β-arrestins.  Different 
active conformations are stabilized with the different chemokines leading to 
stimulation of down stream signaling.  For example, a high affinity agonist of the 
5-HT2C serotonin receptor, a GPCR in same class as the chemokine receptors, 
bufotenin [281] preferentially activates the phospholipase A2 (PLA2)-dependent 
arachidonic acid (AA) release.  While another high affinity agonist, quipazine 
[282], favors the phospholipase C (PLC)-mediated inositol phosphate (IP) 
accumulation pathway [283].  This model of GPCR activation supports that 
different vCXCL-1s activation of CXCR2 (and CXCR1) promotes conformational 
changes leading to specific signaling outcomes.  
In conclusion, our data suggest that the polymorphisms in the HCMV viral 
chemokine, vCXCL-1, bind to CXC chemokine receptors with different affinities 
and elicit various degrees of cellular responses through triggering of diverse 
downstream signals.  This could potentially contribute to HCMV pathogenesis by 
accelerating viral dissemination and/or manipulating the host immune responses. 
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Chapter 5 
SUMMARY AND CONCLUSIONS 
 
Human cytomegalovirus contains a CXC chemokine homolog gene, 
UL146, encoding vCXCL-1.  Previously, vCXCL-1 from the Toledo strain, 
vCXCL-1Tol, was shown to be a functional chemokine for chemotaxis and 
intracellular calcium mobilization in human neutrophils with equivalent potency to 
host chemokines [143].  vCXCL-1Tol can bind both CXCR1 and CXCR2 that are 
preferentially expressed on neutrophils [284] although it was initially reported to 
bind only CXCR2 [143].  Again, the functional ability of vCXCL-1Tol to both 
receptors is similar to that of the host chemokine, CXCL8 (IL-8), even though its 
affinity for each receptor is not as good as CXCL8 (IL-8). Because HCMV can 
infect and replicate abortively in PBN, vCXCL-1’s recruitment of PBN could be 
beneficial for HCMV [285].  Gerna et al showed viral transmission from HCMV-
infected endothelial cells to PBN in vitro after as little as 1 hour of coculture [285].  
HCMV transmission was prevented by lack of contact between the two cell 
populations or by the use of monoclonal antibodies against adhesion molecules 
CD18 and/or ICAM-1.  Therefore, they suggested transient microfusion events as 
a major viral transfer mechanism.  The PBN life cycle is believed a one-way trip 
that ends with apoptosis and/or necrosis in a tissue [286, 287], we believe PBN 
can pick up HCMV from endothelial cells through transitory microfusion events 
and disseminate HCMV through the bloodstream without performing 
transendothelial migration [252] (Fig. 15).   
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Figure 15. PBN associated viral dissemination models. 
(A) PBNs are attracted by host chemokines. (B) PBN shuttle model: vCXCL-1s 
attract more PBNs. PBNs are used for viral dissemination. (C) PBN amplifier 
model: vCXCL-1s induce chemokine production from PBN for attraction of other 
leukocytes such as monocytes, dendritic cells, or Th2 cells. 
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There are two models for the role of vCXCL-1s in HCMV dissemination 
(Fig. 15).  First, the neutrophil shuttle model proposes that the neutrophil is the 
main vehicle for HCMV dissemination [271].  The receptors of vCXCL-1s, 
CXCR1 and/or CXCR2, are expressed to high levels on neutrophils.  Therefore, 
neutrophils can be attracted by vCXCL-1s and can be used a vehicle for HCMV 
dissemination.  In addition to neutrophils, however, CXCR1 and/or CXCR2 have 
been detected on monocyte/macrophages, eosinophils, basophils, CD8 T cells, 
mast cells, and dendritic cells [288-295].  HCMV infection in 
monocytes/macrophages, dendritic cells, CD4 T cells and CD8 T cells were 
reported [252, 275-277, 296].  Therefore, although functional roles of CXCR1 and 
CXCR2 in theses cell types in vivo have not been fully understood, HCMV could 
utilize these cells for possible means for dissemination.    
The second model for the relationship between the viral chemokine and 
neutrophil is the neutrophil amplifier model.  This model focuses the downstream 
effects of neutrophil activation.  In this model, vCXCL-1 leads to neutrophil 
degranulation or expression of cytokines and/or chemokines that promote a 
second inflammatory response that would contribute to HCMV dissemination.  
Either of these scenarios is possible and our data suggests that perhaps both are 
feasible. 
Interestingly, the vCXCL-1s from different HCMV strains are hypervariable 
[26, 27, 155-160] and single nucleotide polymorphisms (SNPs) has been found in 
both CXCR1 and CXCR2 [297, 298].  While the strong association was not 
observed between identified SNPs in CXCR1 and/or CXCR2 from patients with 
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various diseases, such as rheumatoid arthritis, Behçet's disease, or Kawasaki 
disease [297, 299, 300], recently SNPs in CXCR2 can increase their 
susceptibility to periodontitis [301].  Therefore, their variability with in the CXCR 
receptor could lead to combinatorial triggering of different signal transduction 
pathways that could be related to clinical manifestations presented in the 
patients.  Although the hypothesis of this research is that polymorphisms in the 
HCMV chemokine, vCXCL-1, elicit different functions or different levels of cellular 
activation that result in determinant factors of HCMV pathogenesis, the given 
SNP in the receptors could also play role in pathogenesis.  
 To address this, we initially compared the amino acid sequences of 
vCXCL-1s from 51 clinical isolates from 50 congenitally infected children [160].  
18 isolates displayed clinical manifestations such as low birth weight, 
microcephaly, hepatosplenomegaly, jaundice, petechiae, or chorioretinitis.  The 
mature forms without the signal sequence contained between 93 and 98 residues 
with 5% identity (6 residues) (Fig. 2). This includes the four cysteine residues that 
provide the essential structure for CXC chemokines [107].  All sequences were 
assigned to 11 distinct vCXCL-1 clades (Fig. 3).  We found no statistical 
significance between the polymorphisms of vCXCL-1 sequences and HCMV 
sequelae (p=0.37), although three clades showed a high proportion of 
asymptomatic patients: group 8 (88%), group 10 (100%), and group 12 (83%).  
To address whether the vCXCL-1 accumulates mutations under immune 
selection pressure, we analyzed serial HCMV isolates and found no changes in 
vCXCL-1 sequences for up to three years (Fig. 8).   
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Among the differences in alignment, the vCXCL-1TX15 replaces the 
glutamic acid-leucine-arginine (ELR) with the asparagine-glycine-arginine (NGR) 
motif while the other 10 clades have a conserved ELR motif (Fig. 2).  Because 
the ELR motif is important for receptor binding and activation [237, 238], 
modification of the ELR motif could have profound effects on chemokine function.  
Another important receptor binding site, the N-loop region, was also analyzed [36, 
106, 107].  The N-loop region resides between the second cysteine and the 310-
helical turn (approximately 8-10 residues).  Analysis of N-loop sequences divides 
the chemokines into the same 11 clades indicating that the N-loop region is 
mainly responsible for vCXCL-1 variability (Fig. 4).  Since hypervariability occurs 
within binding motifs, such as ELR and N-loop, vCXCL-1s may have different 
affinities for the chemokine receptors and could trigger different downstream 
signaling and subsequent functions.   
In order to address functional variability of the vCXCL-1s, we generated 
recombinant vCXCL-1s from each clade and measured binding affinities and 
performed several functional assays to assess how vCXCL-1 variability affects 
function.  Since the majority of vCXCL-1s contain the conserved ELR motif and 
vCXCL-1Tol binds to both CXCR1 and CXCR2 [28], we measured binding of 
vCXCL-1s to these receptors.  All vCXCL-1s were able to compete with radio-
labeled CXCL8 for binding to CXCR2 with lower affinities compared to CXCL8 
(Fig. 10A).  Nevertheless, three vCXCL-1s, vCXCL-1Tol, vCXCL-1C952, and 
vCXCL-1E760, showed a higher affinity compared to others.  Interestingly, the 
non-ELR CXC chemokine, vCXCL-1TX15, also bound to CXCR2 albeit with very 
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reduced affinity.  When we examined vCXCL-1 binding affinity to CXCR1, we 
found a trend that vCXCL-1s with high affinity to CXCR2 receptors can also bind 
CXCR1 (Fig. 10B), which is similar to CXCL8 which binds to both CXCR1 and 
CXCR2.   
We measured calcium mobilization to evaluate vCXCL-1s ability to 
activate neutrophils and induction of adhesion molecules that may contribute to 
cell-mediated viral dissemination.  All vCXCL-1s showed similar activation 
potentials (Fig. 11) indicating that recombinant vCXCL-1s are capable of inducing 
PBN activation and receptor affinities do not affect calcium mobilization.  vCXCL-
1TX15 also activated PBNs at equivalent levels compared to other vCXCL-1s, but 
was inhibited by a CXCR2-specific inhibitor suggesting vCXCL-1TX15 activates 
PBNs exclusively through CXCR2.  β2-integrins are important in the adhesion 
and extravasation of circulating neutrophils across the endothelium.  All vCXCL-1 
differentially upregulated CD11b and CD11c at equivalent levels to host 
chemokine CXCL1, although any distinct differences in activation potentials 
among the vCXCL-1s were not detected (Fig. 12).   
Based on the binding information of CXCR1 and CXCR2, we analyzed 
chemotactic functions of vCXCL-1s on human PBNs.  Because  CXCL8 (IL-8) 
and vCXCL-1Tol are potent chemoattractants of neutrophils [102, 143] and there 
were little differences in PBN activation between vCXCL-1s (Fig. 11), it was 
surprising when the vCXCL-1s showed different potencies in the induction of 
neutrophil migration (Fig. 13). Interestingly, the differences in neutrophil migration 
potency did not correlate with the differences in affinity for CXCR2 or CXCR1 
 88 
(Fig. 10).  For example, vCXCL-1C954 showed the highest chemotactic index 
among vCXCL-1s, but had one of the lowest affinities (EC50 > 82.2 nM).  
Another functional difference was observed in the induction of CCL22 
(macrophage-derived chemokine (MDC)) production of neutrophil-like HL60 T2 
cells upon vCXCL-1 treatment (Fig. 14).  CCL22 (MDC) attracts multiple immune 
cells, including monocytes, dendritic cells, and the Th2 cells [267].  Although 
neutrophils are the main target for vCXCL-1s and can be used as a vehicle for 
dissemination, the life span of a neutrophil is limited: only a few hours to a few 
days, and they do not multiply.  Monocytes and dendritic cells, on the other hand, 
can survive for months and can multiply.  Therefore, the induction of CCL22 
(MDC) can help HCMV dissemination.  Furthermore, HCMV can productively 
infect macrophages and dendritic cells while they infect neutrophils only 
abortively [252, 272, 302].  An increase in Th2 responses also can help HCMV 
pathogenesis by diminishing CTL responses [118, 119].  From the real-time PCR 
analysis, we found that vCXCL-1s differentially induce CCL22 (MDC) production 
in vitro.  Interestingly, CCL22 (MDC) induction correlated with affinity, unlike 
chemotaxis analysis (Fig. 10).  For example, vCXCL-1C952, vCXCL-1E760, and 
vCXCL-1Tol, showed high affinity for CXCR2 and the highest CCL22 production. 
In conclusion, this study is the first to characterize 11 different HCMV viral 
chemokines, vCXCL-1s.  We showed they are functionally similar to each other 
and to CXCL1 in intercellular calcium mobilization and adhesion molecule 
induction.  There was no correlation between the neutrophil functional data and 
the three clades that trended towards asymptomatic outcomes.  However, we 
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also showed they are functionally different to each other in chemotaxis in an 
affinity independent manner and secondary chemokine production (CCL22) in an 
affinity dependent manner.  There may be other chemokine functions that did not 
show high activity in chemotaxis and CCL22 (MDC) production because all 
vCXCL-1s activate PBN at comparable levels of host chemokines. Future work 
such as the investigation of signal transduction pathways will clarify the 
polymorphisms of vCXCL-1 at the molecular level and provide a better 
understanding of vCXCL-1 and its role in HCMV pathogenesis.   
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Protein production of other viral chemokines 
 
Introduction 
GPCMV encodes a unique, MIP-1 CC chemokine homolog, GPCMV-MIP 
[148].  This gene encodes an 11 kDa protein, which then yields an 8.6 kDa 
mature polypeptide.  Functional assays showed that GPCMV-MIP mobilizes 
intracellular calcium mobilization and chemotaxis via CCR1 receptor exclusively 
[149].  The intracochlear inoculation of a recombinant GPCMV lacking the 
GPCMV-MIP homolog resulted in less hearing loss compared to wild type 
GPCMV infection [186] indicating GPCMV-MIP has roles in CMV pathogenesis. 
The UL147 ORF in HCMV encodes CXC chemokine homolog, vCXCL-2 
[25].  Functional assays of vCXCL-2 are lacking because UL147 is less variable 
than UL146 (i.e. not that many differences between strains) [160] and protein 
production has not been successful.  Recently, it was suggested that vCXCL-2 is 
not secreted and is able to reduce NK activation by downregulating a NKG2D 
receptor ligand, ULBP3 (IHW workshop 2010).  
Previously, viral chemokine productions of GPCMV-MIP and vCXCL-2 
were attempted in our lab but was unsuccesful.  GPCMV-MIP ORF was cloned 
into the baculovirus transfer plasmid pVL1392 and UL147 ORF was cloned into 
TA vector.  This appendix is follow-up study for those viral chemokine 
productions. 
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Materials and Methods 
 
Checking the sequence integrity in vectors   
Previously, the UL147 ORF with an additional 6-His tagged sequence was 
cloned into the baculovirus transfer plasmid pVL1392 (Invitrogen), which contains 
homologous regions for recombination into the baculovirus genome.  To check its 
integrity, the forward and reverse polyhedrin primers were purchased (Invitrogen) 
and used for the DNA sequencing.  The polyhedrin primer regions are located 
outside of the multi cloning site (MCS).  The GPCMV-MIP ORF with 6-Hig tag 
was cloned into the TA vector.  To check its integrity, SP6 and T7 primer were 
used for DNA sequencing.  
 
Site-Directed Mutagenesis 
To fix a single nucleotide substitution of UL147 in pVL1392 vector, the 
site-directed mutagenesis technique was conducted using primers 
(UL147_Fix_Foward: 5’-GAAGTGCTGGCTATTTTAAAGGACAAGGGAACCAAG 
-3’; UL147_Fix_Reverse : 5’-CGTTAGGATTGAGACACTTGGTTCCCTTGTC-3’). 
The PCR condition was 95 °C for 15 min, 35 cycles of 95 °C for 1 min, 55 °C for 
1 min, and 72 °C for 18 min.  The reaction was extended at 72 °C for 15 min.  
DpnI treatment was used to elimnate the original (unmutated) DNA strand. PCR 
was cleanuped using a QIAquick PCR purification kit (QIAGEN) and transformed 
into MAX Efficiency DH5α competent cells (Invitrogen).  After 16 hr incubation 
the colonies were picked and miniprepped for sequencing. 
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Transfer of GPCMV-MIP from TA to pVL1392 
To clone out GPCMV-MIP ORF from TA vector and to delete a redundant 
5’ sequence preceding the start codon, PCR amplification was performed using 
primers (GP526_Fix_Forward: 5’-GCGCTGCAGATGAGAAAGATGAGAGCTTA 
TCTTGGCACAG-3’; GP526_Fix_Reverse: 5’-TCGGAATTCTTAGTGGTGGTGG 
TGGTGGTGTCCTCCGGCCTG-3’). The forward primer has PstI restriction 
enzyme site and the reverse primer has an EcoRI site to give them the correct 
orientation in pVL1392.  The PCR condition was 95 °C for 15 min, 35 cycles of 
95 °C for 1 min, 55 °C for 1 min, and 72 °C for 5 min.  The reaction was extended 
at 72 °C for 10 min.  The PCR-amplified GPCMV-MIP was cloned into the 
pVL1392 vector (Invitrogen) using PstI and EcoRI double digestion.  To check 
the gene integrity, DNA sequencing was performed using the polyhedrin primers 
(Invitrogen).  
 
Production of recombinant viral chemokines 
For the generation of baculoviruses, SF9 cells were transfected with the 
1392/viral chemokine ORF plasmid construct and Sapphire linearized 
baculovirus DNA (Orbigen) according to the manufacturer’s instructions.  
Recombinant baculovirus containing the viral chemokine gene was titrated in the 
small scale (2 ml) of Hi5 cells for optimum protein expression.  Based on the 
small scale titration, the large scale (350-400 ml) of Hi5 cells were used for 
protein production.  48 hrs after infection, supernatants were harvested and 
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recombinant proteins were isolated from the supernatants using Ni-NTA agarose 
beads (Qiagen) for 2 hrs incubation in cold room.  Harvested Ni-NTA agarose 
beads were washed 3 times with PBS.  Proteins were eluted from the beads 
using 0.5 M imidazole for 2 times of 10 min incubation at cold room on the 
rocker.  Eluted proteins were concentrated by Amicon Ultra Centrifugal Filter 
Units (Millipore) with 3 kDa molecular weight cut off.  
 
 
Result and Discussion 
 
 GPCMV-MIP protein production 
GPCMV-MIP ORF was cloned into TA vector.  DNA sequencing revealed 
that it has a redundant nucleotide preceding start codon (Fig. 16A).  Furthermore, 
restriction enzyme sites flanking the ORF were EcoRI, which does not provide an 
orientation upon cloning into pVL1392.  Therefore, when we clone out this ORF 
from the TA vector and put it into pVL1392, we designed primers containing 
different restriction enzyme sites, PstI and EcoRI.  Expected PCR product, a 348 
bp band, was observed (Fig. 17A).  After the PCR product was extracted from 
the gel, both pVL1392 vector and PCR product were double digested by PstI and 
EcoRI (Fig. 17B).  To get rid of any non-specific DNA fragment, digested bands  
 114 
  
 
 
 
Figure 16. The sequences of GPCMV-MIP and UL147 ORF from previous 
work. 
The orange color region is the actual ORF sequences.  The start and stop 
codons are boxed.  (A) GPCMV-MIP ORF cloned into the TA vector showed a 
additional 5’-sequences preceding start codon.  In addition, all restriction enzyme 
sites were EcoRI.  (B) UL147 ORF cloned into pVL1392 showed a 
nonsynonymous substitution.  
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Figure 17. PCR and Cloning of GPCMV-MIP into pVL1392 
(A) Primers with PstI or EcoRI enzyme sites produced 348 bp PCR product.  (B) 
348 bp band was extracted and double digested with PstI or EcoRI.  pVL1392 
vector also double digested with the same restriction enzymes.  (C) To remove 
non-specific DNA fragments, double digested DNAs were extracted from the gel. 
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were extracted (Fig. 17C).  Then, the PCR product was ligated into pVL1392 
vector.  After bacterial amplification of 1392/GPCMV-MIP ORF plasmid construct, 
DNA sequencing confirmed its integrity again (data not shown). 
Transfection/infection into SF9 cells was performed to produce GPCMV-
MIP ORF-containing baculovirus.  When cytopathic effect (CPE) was observed in 
over 90% of SF9 cells, the supernatant containing baculovirus was harvested.  
Small scale of Hi5 cells (2 ml) was used to titrate the baculoviral stock for 
optimum protein expression.  900ul of Hi5 supernatants, 100ul of 10xHBS and 
50ul of Ni-NTA agarose beads (Qiagen) were incubated for 2 hrs and the amount 
of purified protein confirmed on a silver stained SDS PAGE gel.  The expected 
9.4 kDa protein was detected in supernatants from Hi5 cells infected with 10 ul 
input of baculoviral stock (Fig. 18A).  The following large scale production was 
also successful.  Interestingly, another 16kDa band appeared in large-scale 
production (Fig. 18C). There is one N-glycosylation site (N79) in GPCMV-MIP, 
we suspect the 16kDa protein is a glycosylated form of GPCMV-MIP.  PNGaseF 
treatment confirmed it is a glycosylated form as it is deacreased to the 9.4kDa 
upon treatment (Fig. 19).    
 
vCXCL-2 protein production 
UL147 ORF was already cloned into pVL1392 vector.  DNA sequencing with 
polyhedrin primers revealed that it contained a nonsynonymous substitution (A → 
G), which changes lysine to glutamic acid (Fig. 16B).  Therefore, we performed 
site-directed mutagenesis PCR to fix the substitution.  This 
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Figure 18. GPCMV-MIP and vCXCL-2 production. 
(A) Small scale baculoviral stock titration for GPCMV-MIP production. The 
expected 9.4 kDa band begins to appear at 10 ul input supernatant.  (B) 
Baculoviral stock titration for vCXCL-2 in small scale. Expected 8.8 kDa band 
started to appear in 100 ul input supernatant.  (C) Large scale protein production.  
Two distinct bands were observed in GPCMV-MIP while no protein product in 
vCXCL-2 production.  
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Figure 19. PNGaseF confirms GPCMV-MIP glycosylation. 
PNGaseF treatment confirms that a 16 kDa protein is a glycosylated GPCMV-
MIP as it is reduced in size upon treatment.  
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mutagenesis was successfully performed and confirmed by DNA sequencing 
(data not shown).  
Transfection/infection of SF9 cells was performed to produce UL147 ORF-
containing baculovirus.  When cytopathic effect (CPE) was observed in over 90% 
of SF9 cells, the supernatant containing baculovirus was harvested.  Small scale 
infection of Hi5 cells (2 ml) was used to titrate the baculoviral stock for optimum 
protein expression.  The expected 8.8 kDa protein was observed in a 100 ul 
infection of baculoviral stock (Fig. 18B). Following large-scale production, 
however, no protein was isolated (Fig. 18C).  
Penfold et al showed GPCMV-MIP is a functional CC chemokine as it 
induces chemotaxis in hCCR1 expressing L1.2 cells [149].  However, multiple 
minor bands were shown in their SDS-PAGE gel.  They speculated those minor 
bands might be multimers of the 18 kDa species because they did not see any 
mobility of the proteins with endoglycosylase PNGase F.  In contrast, we only 
had two bands in SDS-PAGE and 16 kDa band was disappeared with PNGase F 
treatment. Therefore, we believe our GPCMV-MIP has much higher purity, which 
could generate different results in chemokine function in the same hCCR1 
expressing L1.2 cells or guinea pig cells expressing CCR1 such as neutrophils or 
monocytes.  
Interestingly, UL147 ORF-containing baculovirus expresses protein in a 
small scale but not in a large scale. To confirm whether the protein in a small 
scale is actually vCXCL-2, western blotting with an antibody against the 6 His tag 
could be carried out.  If it is right protein, then protein production on a large scale 
 120 
could be followed.  The possible reasons for why we were not able to purify 
protein on a large scale may be the incorrect volume of viral inoculation or simply 
non-optimal growth conditions for the cells.  If we are able to purify soluble 
vCXCL-2, we can test it all the functional assays for chemokines, such as binding 
assay, calcium mobilization, and chemotaxis.  Because vCXCL-2 protein 
production in soluble form has been unsuccessful, it will certainly help to build 
our knowledge about HCMV pathogenesis as well as being a potential novel 
chemokine. 
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